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Upregulation of specific helpful proteins represents a possible method for preventing or treating human diseases. 
Endogenous upregulation (knockup) is the increase of a gene's expression only in cells in which it is already 
expressed, thus avoiding physiologically abnormal spatiotemporal patterning.
A gene's three prime untranslated region (3′UTR) affects protein expression through stability regulation of RNA 
already transcribed, which suggests 3′UTR modification as a viable route for endogenous upregulation. 
Mammalian model organisms can be generated in order to test the effects of different 3′UTR modifications, but 
at great cost of time, effort, and money.  If able to predict in advance with an in vitro assay whether an in vivo 
modification would cause a desirable or undesirable change, these costs could be substantially reduced.
In this thesis project, an in vitro assay was used to compare the protein expression influence of twenty 
neurodegeneration-relevant mouse genes' 3′UTRs to that of a flip-excision cassette (flex-cassette) previously 
used for in vivo conditional knockup.  The assay used was the Promega Dual-Luciferase Reporter Assay, in 
which plasmids expressing Renilla and Firefly luciferase as reporter and internal control are co-transfected into 
in vitro cells, then each luciferase's expression measured with its respective substrate and a luminometer. 
Transfections were carried out in three-well replicates and on multiple days.
The aims of the project were the evaluation of the assay's ability to predict in vivo results, the suggestion of 
3′UTRs which could be upregulated in vivo by the conditional knockup flex-cassette, and the identification of 
any trends in 3′UTR-based protein expression influence according to gene function.
A number of gene 3′UTRs were identified which were either candidates for flex-cassette upregulation or 
candidates for use in the flex-cassette to upregulate other genes. However, the flex-cassette's in vitro results were
only partially consistent with its previous in vivo results.  Specifically, the lox sites in the flex-cassette was 
observed to lower expression level to a degree not observed in vivo.  Additionally, in the course of the project a 
number of possible workflow improvements were identified, for which suggestions have been made in the text. 
As such, this in vitro approach requires further study in order to determine suitability for prediction of in vivo 
3′UTR behaviour.
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1. Abbreviations used
Throughout this text abbreviations are used for the measurement days and the 3′UTR types used; 
information on these abbreviations can be found in Appendix A.
In gene abbreviations such as bGH (for bovine growth hormone), an initial lowercase ‘m’, ‘b’, or 
‘h’ indicates a mouse, bovine, or human origin respectively.
°C degrees Celsius
3′ three prime
3′UTR three prime untranslated region
5′ five prime
ANOVA analysis of variance
BAC bacterial artificial chromosome
bGHpA bovine growth hormone polyadenylation signal sequence
bp base pair/s (typically of DNA)
CDF cumulative distribution function
control:reporter co-transfection molar ratio of Firefly-lucferase-expressing internal control 
plasmid to Renilla-luciferase-expressing reporter plasmid
CPSF cleavage and polyadenylation specificity factor (protein complex)
CstF cleavage stimulation factor (protein complex)
DNA deoxyribonucleic acid
flex-cassette flip-excision cassette (Schnütgen et al., 2003 and 2005), for which Cre 
recombinase irreversibly flips a sequence's orientation
kb or kbp kilobase/s or kilobase pair/s (one kilobase equivalent to 1000 bases)
ml millilitre/s
mRNA messenger RNA
N/A not applicable
NCBI National Center for Biotechnology Information
n.d. no date
ng nanogram/s
n.n. no name
RNA ribonucleic acid
SOC medium super optimal broth with catabolite repression
µg microgram/s
µg/ml micrograms per millilitre
µl microlitre/s
UV ultraviolet
PCR polymerase chain reaction
TAE Tris-acetate-EDTA (buffer)
Tm theoretical temperature at which half of a primer's molecules are annealed and 
half unannealed, used as the annealing temperature in PCR
V volts
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3. Introduction
3.1. Treatment design for cell dysfunction diseases
3.1.1. Protein- versus DNA-level treatment
A cell's behaviour is controlled by its genetic and epigenetic information.  Human protein-coding 
genes produce tens of thousands of proteins which function in regulated coordination to keep their 
cell in working order (Hahn and Wray, 2002).  Disruptions to either protein coding sequence or 
protein expression regulation can give rise to a multitude of different pathologies, and 
pharmaceutical compounds or other tools which directly interact with proteins—protein-level 
methods—must be designed according to the structure and behaviour of each protein target (Chen et
al., 2012).
By contrast, tools for genetic or epigenetic manipulation which can be used for any and all genes—
DNA-level methods—do not have this limitation.  Instead of expending money and time to develop 
and test an effective protein-level treatment for only one disease, then begin again from scratch for 
the next disease, a tool which affects protein generation requires development in theory only once 
before it can be used in testing for all genes, as all genes in a genome are encoded with the same 
storage format (Gurevich and Gurevich, 2015).
Further, if treatment is protein-level in nature and does not originate from the DNA inside target 
cells, specificity is difficult.  A protein-level treatment will affect all susceptible cells exposed to it, 
as in when dopaminergic axons have grown towards a glial cell line-derived neurotrophic factor 
(GDNF) injection site rather than towards their physiological targets (Ibáñez and Andressoo, 2017). 
By contrast, working at the DNA level can allow conditional outcomes through expression 
regulation, without adversely affecting unrelated cells.
3.1.2. Protein sequence alteration versus protein expression alteration
Ultimately, manipulation of both protein sequence and protein expression are necessary for 
maintained cell health, both develop problems in the face of adverse conditions or the passage of 
time (Milholland et al., 2017).  Dysfunctionally-expressed functional proteins and functionally-
expressed dysfunctional proteins are both inadequate for cell functionality.
Both manipulation approaches lend themselves soonest to the treatment of inherited genetic 
disorders, in which all of a person's cells possess the same pathogenic allele and there exist people 
possessing non-pathogenic versions of that allele which can be used as templates for all accessible 
cells simultaneously.  New mutations and epigenetic changes such as from aging are instead 
different for each affected cell, requiring either logistically infeasible cell-by-cell treatment or else 
beneficial alterations to all cells for prevention or mitigation of categories of problems which have 
similar effects.
If attempting beneficial alterations through protein sequence alteration, lacking a human template 
for the alteration desired, the challenge of designing the new protein structure according to its 
desired behaviour is even harder than that for pharmacuetical design, due to the complexity 
involved in protein-folding and protein domain interaction.
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By contrast, expression alterations make use of existing protein structures and interactions while 
only modulating their effects through dosage, aiming for qualitative improvements with few 
uncertain factors—‘low-hanging fruit’ to be picked first.
3.1.3. Desirable protein expression changes
As part of the Andressoo research group's focus on neurodegeneration, attention has been paid to 
proteins in the categories of aggregation, anti-aggregation, and neuron survival.  Aggregation 
proteins like amyloid beta for Alzheimer's disease are expressed in the first place because of their 
genes' beneficial or necessary functionality (Corrigan et al., 2012), but in a failure of autophagy can 
form harmful aggregates (McCray and Taylor, 2008).  Anti-aggregation proteins are those which in 
healthy cells prevent the formation of pathogenic aggregates (Gao et al., 2015).  Neuron survival 
proteins are those which stop neurons from dying despite not affecting their pathogenic aggregates; 
for GDNF, which promotes dopaminergic neuron survival, it is hoped that higher levels of GDNF 
could prolong or otherwise maintain neuron survival in Parkinson's disease patients (Kumar et al., 
2015).
As with anti-aggregation proteins, increased thoroughness of DNA maintenance proteins offers to 
reduce the rate of new mutations in the first place.  Particularly in the area of DNA double-strand 
break repair (Tian et al., 2017), there is correlation between repair gene expression and organism 
lifespan.
A common trend is of desirable beneficial alterations being in the form of increased expression of 
genes with beneficial functionality, with decreased expression only desired in cases where 
expression is already pathogenically abnormal.
3.1.4. Types of expression alteration possible
Within a given cell, for a protein's dosage rather than its localisation or other behaviour there are 
only four types of expression alteration possible:  making non-zero expression zero, making zero 
expression non-zero, decreasing expression without eliminating it entirely, and increasing 
expression.  These can be thought of as ‘1-to-0’, ‘0-to-1’, ‘less’, and ‘more’.
Non-zero expression being made zero (‘1-to-0’) is referred to as a knockout, and can be 
accomplished by excising from the genome either an entire gene or a critical component of that 
gene.
Making zero expression non-zero (‘0-to-1’) is not referred to symmetrically as a knockin, as the 
term knockin is already used for any targeted genomic insertion or replacement, unrelated to the 
resulting effect on protein expression.  Instead, the term exogenous overexpression can be used for 
this, in which a protein is expressed from a plasmid or genomically-inserted coding sequence copy 
separately from its native allele, or else expressed from the native copy in cell types which would 
otherwise not express it.  Exogenous overexpression can be used for either 0-to-1 expression or 
adding expression to expression already present; however, different overexpression contexts can 
result in very different expression patterns (Maskri et al., 2004).  Exogenous overexpression is thus 
less reliable for reproducible treatment testing or gene-function interrogation than the other 
expression alteration types, which alter already-present expression from a native allele 
endogenously, without changing its spatiotemporal patterning.
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Expression being decreased (‘less’) is referred to as a knockdown, and is accomplished for instance 
through the introduction of morpholinos which temporarily block messenger RNA (mRNA) 
translation.
Expression being increased (‘more’) by symmetry can be referred to as a knockup, and is an 
increasing of native expression only where already present.  As such, this rules out any approach 
which alters a gene's promoter or other upstream regulatory sequence which controls in which cell 
types the protein is expressed.
3.1.5. Three prime untranslated region (3′UTR) knockup
Regulatory sequences at the five prime (5′) end of a gene, influenced by related enhancers, control 
whether it is transcribed or not in each cell.  As transcription progresses from the mRNA's 5′ end to 
its three prime (3′) end, the primary transcript undergoes capping, splicing, and cleavage-and-
polyadenylation; this produces a mature mRNA with a cap, a 5′ untranslated region, a protein-
coding translated region beginning with a start codon and ending with a stop codon, a three prime 
untranslated region (3′UTR), and a poly(A) tail (Fig. 1).
Known 3′UTRs are of 19 to 19,142 nucleotides long (Mignone, 2002).  Transcription begins and 
proceeds from the gene's promoter at the 5′ end, while the 3′UTR takes a leading role 
posttranscriptionally by controlling poly(A) tail initial length and degradation rate through binding 
sites for microRNAs and RNA-binding proteins (Jalkanen et al., 2014).  Binding sites for 
microRNAs for example are largely constrained to the 3′UTR (Shivdasani et al. 2006; Gu et al., 
2009), and allow posttranscriptional regulation of different mRNAs according to which microRNAs
each cell type expresses (Fig. 2).  As an mRNA with a fully-degraded poly(A) tail is decapped and 
destroyed, this determines how long on average an mRNA molecule survives, and thus how many 
protein molecules on average are translated from each mRNA molecule.
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Figure 1. An example of messenger RNA (mRNA) structure, adapted and modified from "Insulin synthesis involves 
multiple post-translational cleavages of polypeptide precursors", Figure 1.26 of the fourth edition of Human Molecular
Genetics (Strachan and Read, 2010).  The mRNA three prime untranslated region (3′UTR) is transcribed from genomic
DNA, but not translated into an amino acid sequence.
This suggests the 3′UTR as a way to accomplish gene knockup, for example through targeted 
ablation of binding sites for microRNAs known to be highly expressed in the cell type or types of 
interest, ablation of other sequences known to decrease mRNA half-life, or instead by insertion of 
sequences known to increase mRNA half-life such as the cytoplasmic polyadenylation element.
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Figure 2.  Expression downregulation through the 3′UTR, adapted and modified from 
"Posttranscriptional Gene Silencing" (Pressman et al., 2007).  This figure depicts 
microRNAs (miRNAs) and their role in reduction of messenger RNA (mRNA) translation.
miRNPs are microRNA ribonucleoprotein complexes.
3.2. Non-human testing
3.2.1. In vivo modelling with a conditional knockup flex-cassette
Before implementation as a human medical treatment, the process must first undergo non-human 
testing:  even for humans facing the prospect of brain death, treatments attempted can thus be 
limited to those which have offered satisfactory results in non-human models, following the three 
Rs of Replacement, Reduction, and Refinement propounded in 1959 by Russell and Burch 
(Emerson, 2010).
Rather than using a treatment method for adult animals, genetically-modified models were grown 
from embryonic stem cell clones.  While treatment methods in adult humans might achieve varying 
levels of cell-affecting efficiency, a modification present in all cells allows theoretically 100% 
efficiency, which is desirable both for proof-of-concept assessing whether a treatment has hope of a 
positive result and for assessing whether that extreme 100% efficiency can bring about observable 
negative effects.  It can also be noted that hypothetical future technological advances in adult-
treatment efficiency could allow application of information about high-efficiency treatment results 
that might not have been obtainable if using a less-efficient technology to test the effects.
For initial human-relevant in vivo modelling, the mouse is currently the most favoured organism 
due to that it is mammalian, readily available, and has a number of well-established genetic 
modification methods (Nguyen and Xu, 2008; Ellenbroek and Youn, 2016).  That said, while the 
time cost of growing few or many mouse models to adulthood is similar, the monetary cost of 
feeding and other care is not small, and varies proportionately with the number of mice being cared 
for.  For a proof-of-concept in vivo test, a multitude of mice with many different alterations to each 
gene-of-interest's 3′UTR is monetarily and ethically wasteful:  if critical information about the 
feasibility of 3′UTR alteration can be obtained through a less costly workflow, then again by the 
three Rs those excess resources should be used where more worthwhile.
When testing knockup of many genes, a single reliable alteration that could be applied in an 
assembly-line manner would also save time that would otherwise go into separately interrogating 
each gene's 3′UTR for individual modification.
For proof of concept experiments, the Andressoo research group tested the potential of 3’UTR 
alteration gene knockup by removing all native 3′UTR regulatory elements.  This was done through 
the insertion of a different 3′UTR, thought to impart a long mRNA half-life, at the beginning of the 
native 3′UTR.  After the inserted 3′UTR's cleavage-and-polyadenylation, all the native 3′UTR 
regulatory elements are thus in the cleaved-away downstream portion.  The replacement 3′UTR 
used is the bovine growth hormone polyadenylation signal sequence (bGHpA), which displayed the 
highest effect on expression in a paper which tested the effects of different 3′UTRs on protein 
expression in mouse genetically-modified embryonic stem cells (Kakoki et al., 2004).
The result of this was the GDNF hypermorphic mouse, which exhibited increased GDNF mRNA 
levels and protein expression in the striatum, but also defective kidneys when homozygous due to 
the role of GDNF in kidney development (Kumar et al., 2015).
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Building on this, the next form of gene knockup that the Andressoo research group has tested is a 
bGHpA flex-cassette, for which backward-orientation bGHpA is irreversibly excision-flipped to 
forward-orientation only in the presence of Cre recombinase (Schnütgen et al., 2003 and 2005).  By 
crossing these conditional knockup mice with specific Cre recombinase expressing mouse lines, or 
by introducing Cre recombinase with viral delivery, upregulation can be induced at different 
developmental stages and/or different tissues and cell types (Mätlik et al., 2019).
In GDNF conditional knockup mice with ubiquitously-expressed Cre, the kidney size was reduced 
as in the GDNF hypermorphic mouse. However, in GDNF conditional knockup mice with Cre 
expressed from a Nestin promoter, GDNF knockup was restricted to the central nervous system.  In 
both cases GDNF mRNA levels were elevated (Fig. 3), but much more so in the kidney, thought to 
be due to cell-type-dependent differences in GDNF wild-type mRNA half-life.
3.2.2. In vitro modelling with a dual-luciferase assay
Though the aim has been to achieve a large effect by complete replacement with a long-half-life 
3′UTR rather than incrementally increase the existing 3′UTR's half-life, the effect could be 
knockdown rather than knockup if replacing a 3′UTR which granted a longer half-life in a given 
cell type than the replacement 3′UTR.
As the protein expression of genes in vivo is affected by 5′ transcriptional regulation and not only 
by 3′UTR posttranscriptional regulation, the effect of the flex-cassette cannot be predicted from 
wild-type in vivo expression levels.  Again following the three Rs, it would be helpful to be able to 
test the effect of a flex-cassette on a 3′UTR's half-life in vitro before committing to the temporal, 
monetary, and ethical responsibility of constructing a mouse model to observe the physiological 
consequences.   A suitable in vitro assay could keep everything other than the 3′UTR constant, 
allowing direct comparison of a gene-of-interest's 3′UTR and its proposed replacement.  That in 
vitro work is the focus of this thesis project.
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Figure 3.  GDNF conditional knockup mRNA increases, 
adapted and modified from (a) “Endogenous GDNF in 
the kidney” and (b) “Endogenous GDNF in the brain of 
adult GdnfcKU;Nestin-Cre mice”, Figure 2a and Figure 3a 
respectively of an Andressoo research group paper 
(Mätlik et al., 2019).  These are the in vivo results of 
bGHpA flex-cassette conditional knockup in the mouse 
GDNF 3′UTR.  wt is wild type, cKU is the conditional 
knockup allele, and +Cre indicates the presence of the 
Cre recombinase which excision-flips the flex-cassette's 
bGHpA sequence to its active forward-orientation.  
Pgk1-Cre is Cre recombinase expressed from a 
phosphoglycerate kinase 1 promoter, and Nestin-Cre is 
Cre recombinase expressed from a Nestin promoter.
In vitro comparison of 3′UTR effects on protein expression has been done before, but with greater 
inconvenience.  Kakoki et al. used flow cytometry of mouse embryonic stem cells, which required 
genomic sequence insertion and colony-picking of drug-resistant cells (Kakoki et al., 2004).  Zhao 
et al. used lentiviruses and quantitative real-time PCR (polymerase chain reaction) (Zhao et al., 
2017), which require biocontainment precautions and painstaking following of MIQE guidelines 
(Bustin et al., 2009).  Promega Corporation's Dual-Luciferase Reporter Assay System (catalogue 
number E1960), instead, only requires cell line cells to undergo co-transfection, culturing, and lysis 
prior to measurement.  In the dual-luciferase assay, Firefly luciferase and Renilla luciferase are 
transcribed from identical promoters with optionally different 3′UTRs (Fig. 4, 5, and 6); 
transcription is from two co-transfected plasmids rather than a single plasmid so that the same 
promoter can be used while co-transfecting in a molar ratio that avoids trans effects.
Having an internal control allows normalisation for not only transfection efficiency differences, but 
also any effect on transcription or translation efficiency resulting from different amounts of reporter 
protein generated.
In this thesis, mouse rather than human 3′UTRs have been used for the sake of deciding what genes 
to target in future conditional knockup in vivo mouse models.  However, a human embryonic 
kidney cell line was used as it was already possessed by the Andressoo research group, while also 
having fast growth with high transfection efficiency (data not shown).
By the end of the thesis project, the dual-luciferase assay was used to compare the influence on 
protein expression of the native 3′UTRs of twenty mouse genes to the bGHpA flex-cassette in both 
its backward and excision-flipped orientations (Fig. 5).  These genes were selected from the 
neurodegeneration-relevant categories of aggregation, anti-aggregation, and neuron survival, and 
include the mouse GDNF gene for which in vivo testing has previously been done.
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Figure 4. Plasmid structures of (a) pGL4.13 and (b) pGL4.73.  The two plasmids are identical except for the
luciferase coding sequence.  pGL4.13 was used as an unaltered co-transfection internal control, and pGL4.73
was used as a backbone for 3′UTR modification.  The luciferase is expressed eukaryotically while the 
Ampicillin resistance is expressed prokaryotically.  The illustrations are adapted and modified from the 
‘Graphic Map’ display option of the plasmid-map software ApE version 2.0.51.  No restriction sites are 
displayed other than those of XbaI and SalI, which were used in this thesis for 3′UTR modification.
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Figure 5.  bGHpA flex-cassette (Schnütgen et al., 2003 and 2005) in (a) unflipped and (b) excision-flipped orientations 
upstream of the SV40 3′UTR in plasmid pGL4.73 (Fig. 4b).  The pGL4.73 sole SalI restriction site is marked, but the 
pGL4.73 XbaI restriction site between the luciferase coding sequence and SV40 3′UTR no longer exists after flex-cassette 
insertion.
Figure 6. Genomic 3′UTR PCR primer positions, not to scale and without marked introns.  Outer nested primer (OuterF, 
OuterR) and restriction-site-extension inner nested primer (InnerF, InnerR) annealing locations are marked with blue 
arrows.  These primers were used for PCR of mouse genes' 3′UTRs (without including the stop codon) in order to replace 
the SV40 3′UTR following the Renilla luciferase coding sequence in plasmid pGL4.73 (Fig. 4b).  Where the mouse gene 
3′UTR contained an XbaI restriction site, an NheI or BcuI restriction site was used instead in the InnerF extension to 
produce an identical 5′ overhang in later restriction digestion without also cutting apart the PCRed 3′UTR.
4. Aims
3′UTR expression levels from twenty mouse genes were measured with two purposes in mind.  If 
the expression level of a 3′UTR is much lower than that of the bGHpA flex-cassette, then that 
3′UTR is a candidate for upregulation with the bGHpA flex-cassette in a mouse model.  If instead 
the expression level of a 3′UTR is much higher than that of the bGHpA flex-cassette, then that 
3′UTR's sequence is a candidate for replacement of the bGHpA sequence in the bGHpA flex-
cassette, in order for the flex-cassette to be more effective in inducing expression level 
upregulation.
One aim of this project is thus the sorting of different genes' 3′UTRs' with these two purposes in 
mind.
If there were correlation between gene category and 3′UTR expression level, this was also viewed 
as worth noting for relevance in future research, such as whether disease-associated aggregation 
proteins associated consistently exhibited 3′UTRs with high expression levels.
The bGHpA flex-cassette in different orientations was measured both for assessment of the twenty 
mouse genes' 3′UTRs' expression levels and to compare its in vitro behaviour to in vivo behaviour 
previously observed.  Namely, an aim was to observe whether a reverse-orientation bGHpA flex-
cassette at the start of a 3′UTR had negligible effect on that 3′UTR's expression level and whether a 
forward-orientation bGHpA flex-cassette at the start of a 3′UTR replaced that  3′UTR's expression 
level with an expression level much higher than that from mouse GDNF's 3′UTR.
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5. Materials and Methods
5.1. Plasmid amplification
Large yields of Promega Corporation's pGL4.13 Firefly luciferase plasmid (Fig. 4a) were produced 
for use as an internal control in all transfections.  A large yield of Promega Corporation's pGL4.17 
Renilla luciferase plasmid (Fig. 4b) was likewise produced, but this instead both for use as a 
plasmid backbone to prepare multiple reporter plasmids, and as an unmodified high-expression 
reference reporter to be transfected many times.
In all large-yield plasmid replications in this project, the plasmid underwent heat-shock 
transformation into calcium chloride chemically competent DH5alpha E. coli bacteria.  After 1-hour
outgrowth in super optimal broth with catabolite repression (SOC medium), the transformed 
bacteria were cultured overnight in 100 millilitres (ml) of LB medium containing 100 micrograms 
per millilitre (μg/ml) Ampicillin.  A small portion of that culture was separated to make a −80°C 
bacterial glycerol stock and the rest made into a pure extracted-plasmid midiprep with Macherey-
Nagel's NucleoBond Xtra Midi kit (catalogue number 740410.50).  The purpose of the glycerol 
stock was to allow reculturing without retransformation should replenishment of a stored plasmid 
become necessary.
Where large yields were unnecessary, as for a reporter plasmid to be transfected a small number of 
times, a miniprep extraction was carried out instead from a 3 ml culture with Macherey-Nagel's 
NucleoSpin Plasmid miniprep kit (catalogue number 740588.250).  
Throughout the thesis project, all midiprep and miniprep extractions were performed with these two
kits except where specified otherwise.
The concentration of each plasmid preparation was measured with Thermo Fisher Scientific's 
NanoDrop 2000 Spectrophotometer (catalogue number ND-2000) following vortexing with 
Scientific Industries's Vortex Genie 2 (catalogue number SI-0236).
For convenience of dilution and of concentration-measurement blanking, all plasmid elution and 
dilution was done with sterile water rather than extraction kit elution buffer.
5.2. Reporter plasmid construction
The (+SV40) 3′UTR type plasmid (all 3′UTR abbreviations explained in Appendix A) is the 
unmodified pGL4.73 plasmid (Fig. 4b) containing the simian vacuolating virus 40 (SV40) 3′UTR 
sequence.  Other reporter plasmids were constructed by inserting sequences before pGL4.73's SV40
3′UTR or by replacing the SV40 3′UTR sequence entirely (Fig. 5 and 6).  The 
+mGDNF+60p(+SV40) 3′UTR type plasmid alone was made in the same way by an Andressoo 
research group former member in an earlier project.
5.2.1. Primer design
For genes-of-interest, mouse gene 3′UTR sequences were obtained initially from the National 
Center for Biotechnology Information (NCBI) Gene database 
( https://www.ncbi.nlm.nih.gov/gene/ ), and later from the Ensembl Genome Browser 
( https://www.ensembl.org/index.html ), as indicated in Appendix A.  
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The bGHpA flex-cassette and WPRE+hGH sequences used for certain 3′UTR types were amplified 
from plasmids already possessed by the Andressoo research group.  Appendix B records template 
sequences from these plasmids which were used for primer design and PCR.
PCRs from genomic DNA were initially carried out in the same way as for plasmids and Bacterial 
Artifical Chromosome (BAC) clones, with one primer pair each.  The primers-half-annealed 
temperature (Tm) was also initially different for each primer pair, and thus had PCR programs with 
different annealing temperatures.
For reporter plasmids designed later, genomic DNA PCRs were carried out with nested primers in 
order to increase PCR specificity and the yield of the desired product.  Outer nested primers were 
designed with NCBI's Primer-Blast ( https://www.ncbi.nlm.nih.gov/tools/primer-blast/ ), while inner
nested primer design was carried out in the same way as for plasmid and BAC clone PCRs.
For most genomic 3′UTR sequences used, forward and reverse inner nested primer annealing-
region sequences were chosen with their 5′ ends at the beginning and end respectively of the 
reference sequence's annotated 3′UTR (Fig. 6).  Where specified (the '-extended' 3′UTR types), the 
reverse primer 5' end was selected with Primer-Blast so as to include at least 500 base pairs (bp) 
from after the annotated end of the 3′UTR.  Primer 3′ ends were initially designed according to 
Primer-Blast-predicted PCR product specificity, then later according to an annealing-region Tm of  
60°C as predicted by the plasmid-map software ApE (‘A plasmid Editor’) version 2.0.51.
After the design of inner nested primers' annealing-regions, desired restriction sites for cloning 
(described further in subsection 5.2.3) were added to their 5′ ends, together with a further-five-
prime AT-rich 6-nucleotide leading sequence to enable restriction digestion (NEB, ‘Cleavage Close 
to the End of DNA Fragments’) while mitigating any increase of non-specific annealing. Primer-
dimer formation risk was predicted with Thermo Fisher Scientific's Multiple Primer Analyzer 
( https://www.thermofisher.com/fi/en/home/brands/thermo-scientific/molecular-biology/molecular-
biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/multiple-
primer-analyzer.html ), and primer length or leading sequences were changed as necessary to reduce
primer-dimerisation likelihood.  
Once the design process was complete, primers were ordered in the form of single-stranded DNA 
oligonucleotides from Metabion.  All primers used in the course of this project are listed in 
Appendix C.
5.2.2. PCR of 3′UTR sequence inserts
To increase the yield and specificity of PCR products, Touchdown PCR (Table 1) using Thermo 
Fisher Scientific's Phusion High-Fidelity DNA Polymerase (catalogue number F530S) was carried 
out.  The PCR machine used was Applied Biosystems's SimpliAmp Thermal Cycler (catalogue 
number A24811).
Mouse genomic DNA was obtained from mixed-background mouse tail tissue samples with VWR 
International's Quantabio AccuStart II Mouse Genotyping Kit (catalogue number 733-2236).  
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Outer nested primer PCR product samples were used as inner nested primer PCR templates, after 
dilution with sterile water such that the inner nested primer PCR mixture only possessed one 
thousandth the concentration of genomic DNA of the outer nested primer PCR mixture.  This was 
after an agarose gel comparison of the effect of different dilutions (data not shown), and with the 
purpose of further reducing undesired PCR products.
Where there was persistent difficulty in amplifying specific 3′UTR sequences from genomic DNA, 
mouse BAC clones in E. coli strain DH10B were ordered from the BACPAC Resources Centre, 
cultured with 12.5 µg/ml chloramphenicol, then the BAC clones extracted with DNA precipitation 
and repeated 70% ethanol washing instead of with a spincolumn, as the BAC clone sizes exceeded 
160 kilobases (kb) and the Macherey-Nagel miniprep kit's manual described it as only suitable for 
vectors smaller than 50 kb (NucleoSpin Plasmid manual Table 1).  In retrospect it should have been 
possible to use the Macherey-Nagel midiprep kit instead, as its manual describes it as suitable for 
BACs and other very large constructs between 3 kb and 300 kb (NucleoBond Xtra Midi manual 
section 2).
Table 1.  The Phusion Touchdown PCR program used by the end of the project.  kbp is kilobase pairs (of DNA).
Denaturing Annealing Extension Hold
Stage 1 (1 cycle)
30 seconds
98°C
- - -
Stage 2 (10 cycles)
10 seconds
98°C
30 seconds 
70-to-61°C
(AutoDelta -1°C
each cycle-end)
30 seconds per kbp of
longest product 
72°C
-
Stage 3 (20 cycles)
10 seconds
98°C
30 seconds
60°C
30 seconds per kbp of
longest product 
72°C
-
Stage 4 (1 cycle) - - -
Until retrieval
4°C
5.2.3. Restriction digestion for cloning 
3′UTR PCR products and Promega Corporation's pGL4.73 plasmid (Fig. 4b) were digested 
separately with Thermo Fisher Scientific's FastDigest restriction enzymes, specifically FastDigest 
XbaI, FastDigest NheI, FastDigest BcuI, and FastDigest SalI as required (respectively catalogue 
numbers FD0684, FD0973, FD1253, and FD0644). FastDigest XbaI, FastDigest NheI, and 
FastDigest BcuI produce identical 5′ overhangs (Table 2), and so FastDigest NheI or FastDigest 
BcuI were used when a 3′UTR sequence contained XbaI restriction sites.  No such replacement was
needed for FastDigest SalI.  Digested pGL4.73 plasmids were dephosphorylated in the same 
reaction with Thermo Fisher Scientific's FastAP Thermosensitive Alkaline Phosphatase (catalogue 
number EF0651) to prevent vector-vector ligation.
Table 2.  Restriction sites of the restriction enzymes used, for which XbaI, NheI, and BcuI produce identical 5′ 
overhangs.  ' refers to a sense strand cut and . refers to an antisense strand cut.
Restriction site (FastDigest) enzyme Restriction site sequence
XbaI T ' CTAG . A
NheI G ' CTAG . C
BcuI A ' CTAG . T
SalI G ' TCGA . C
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5.2.4. Electrophoresis and gel purification
For the sake of a low proportion of non-specific PCR products in ligation, digested PCR products 
were purified from agarose gels after electrophoresis.  In order to reduce undigested plasmid DNA, 
the digested pGL4.73 plasmid backbone used for plasmid construction was similarly purified from 
an agarose gel after electrophoresis.
Agarose gels were made from Tris-acetate-EDTA (TAE) buffer prepared by the University of 
Helsinki and agarose from Thermo Fisher Scientific (catalogue number 10776644).  1% agarose 
gels were used for desired product lengths over 750 bp and 3% for under 750 bp, to maximise 
differences in running distances (Lee et al., 2012).  To prevent well overflow, agarose gel volumes 
were 100 ml when loading samples of 12 microlitres (µl) or less and 150 ml if loading any sample 
between 12 and 30 µl.  Sample lane wells were prepared during gel setting using a 20-well Bio-Rad 
comb (catalogue number 1704448).  
Initially, agarose gels were made with ethidium bromide and DNA bands visualised with ultraviolet 
(UV) transillumination during excision.  To avoid DNA damage from using a UV transilluminator 
(ThermoFisher Scientific, ‘SYBR Safe - DNA Gel Stain’; Gründemann and Schömig, 1996) , later 
gels were instead made containing 0.001% crystal violet (from Thermo Fisher Scientific, catalogue 
number 10637884), for which high-yield DNA bands are visible in normal light conditions (Rand, 
1996).
In the final workflow, to allow visibility of low-yield DNA bands while preventing UV DNA 
damage, agarose gels were made with 0.0001% SYBR Safe DNA Gel Stain (from Invitrogen, 
catalogue number S33102), and gel slices containing DNA bands were excised using Bio-Rad's 
ChemiDoc MP Imaging System (catalogue number 12003154) and its Blue Sample Tray (catalogue 
number 12003027), together with Bio-Rad's XcitaBlue Viewing Goggles (catalogue number 
1708185) for filtering out blue light while leaving the emitted fluorescence visible.
Thermo Fisher Scientific's GeneRuler 1 kb DNA Ladder (catalogue number SM0311) was used in 
all gels to identify approximate DNA molecule lengths.
Agarose gel electrophoresis itself was carried out in Bio-Rad's Sub-Cell GT Horizontal 
Electrophoresis System, 15x25 cm tray (catalogue number 1704404), for 3 hours at 55 volts (V).  
The purification kit used after gel slice excision was Macherey-Nagel's NucleoSpin Gel and PCR 
Clean-up kit (catalogue number 740609.250), and the running voltage below 60 V was selected 
according to its manual's recommendation (NucleoSpin Gel and PCR Clean-up manual subsection 
2.5).  Following purification, DNA concentration was measured with with the same NanoDrop 
spectrophotometer used for plasmid concentration measurement.  As with plasmid extraction, sterile
water was used in place of elution buffer for elution and dilution.
5.2.5. Ligation of insert and backbone
Ligation of purified inserts into purified plasmid backbones were carried out with Thermo Fisher 
Scientific's T4 DNA Ligase (catalogue number EL0014).
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After transformation (as in subsection 5.1), colonies were grown on LB agar plates containing 100 
μg/ml Ampicillin.  Liquid cultures were grown from individual colony samples, then miniprep 
plasmid extractions carried out (also as in subsection 5.1).  Restriction analysis was done with 30-
minute 120 V ethidium bromide agarose gel electrophoresis and UV transillumination for initial 
analysis of the clones by comparing observed DNA fragment sizes to fragment sizes predicted by 
ApE version 2.0.51.  For seemingly-successful plasmid constructs this was followed by Sanger 
sequencing, more expensive than restriction analysis, for final confirmation.  Sanger sequencing 
was also carried out to check the +mGDNF+60p(+SV40) 3′UTR type plasmid previously produced 
by an Andressoo research group former member.
5.3. Co-transfection
Using Thermo Fisher Scientific's TurboFect transfection reagent (catalogue number R0531), the 
HEK-293 human embryonic kidney cell line (ATCC number CRL-1573) was co-transfected in a 96-
well cell culture plate's well with a subsection 5.2 reporter plasmid together with Promega 
Corporation's pGL4.13 plasmid (Fig. 4a) as an internal control.  Co-transfection masses were 
calculated according to the NanoDrop-measured DNA concentrations and predicted reporter 
plasmid lengths to implement a consistent molar ratio of internal control plasmid to reporter 
plasmid within wells measured on the same day.  
All wells transfected in the same day were also measured in the same day.  Any well transfected 
was part of a replicate of three wells transfected with the same co-transfection mix.  Each cell 
culture plate used for transfection contained replicates for different reporter plasmids which could 
thus be directly compared to each other.  Identical co-transfection plans were carried out on three 
different days where time allowed, each plate's wells to undergo measurement together on a 
different day.
5.4. Measurement recording
Firefly and Renilla luminescence was induced in turn with the luciferase substrates of Promega 
Corporation's Dual-Luciferase Reporter Assay System (catalogue number E1960) and measured 
with Promega Corporation's GloMax 20/20 Luminometer (catalogue number E5311), which 
measures luminescence from one Eppendorf tube at a time and thus avoids all crosstalk.  The 
measurement program was a 2-second preread delay followed by a 10-second measurement period, 
first after mixing with the Firefly luciferase substrate and again after then mixing with the Renilla 
luciferase substrate, which also quenches Firefly luciferase activity.  As the measurement steps 
should be done quickly and identically, cell culture plate well lysates were all transferred to labelled
Eppendorf tubes after cell lysis to prevent losing track of wells while making measurements.
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Normalised measurements for the wells were calculated as Renilla luminescence divided by Firefly 
luminescence, to correct for differences in cell number and expression efficiency between wells.  As
the GloMax 20/20's detector is a photomultiplier tube (Glomax 20/20 manual subsection 12.G.) 
which gives lognormally-distributed results (Kissick et al., 2010), measurements can be 
logarithmised to produce normally-distributed values.  Unlike lognormal distributions, normal 
distributions ideally have symmetrical distribution about a true parameter being measured, and thus 
are more visually intuitive for estimating that true parameter.  Logarithmisation to the base 2 was 
chosen, with a distance of 1 equating to a 2-fold difference.  As log2(x/y) = log2(x) - log2(y), and 
the difference of normally-distributed random variables is also normally-distributed, each 
Renilla/Firefly normalised measurement in each replicate was logarithmised directly to produce 
normally-distributed data points.
 
5.5. Statistical analysis
5.5.1. Testing of samples for homogeneity of variance
Using logarithmised measurement ratios, Levene's test was carried out with PSPP version 1.2.0.  
Empirical cumulative distribution function comparison to chi-squared distributions was carried out 
using the CHISQDIST function of LibreOffice Calc in LibreOffice version 6.2.8.2 (x64).
5.5.2. Testing of samples for normality
Sample residuals underwent normality testing in R version 3.6.2.  A Shapiro-Wilk normality test 
was carried out with shapiro.test(), and a Q-Q plot for normality testing was carried out with 
qqnorm() and qqline().
5.6. Day-adjustment normalisation of recorded data points
As suggested by the dual-luciferase assay's manual, the freezing and thawing history of the Firefly-
luciferase's substrate can change the amount of light produced per luciferase molecule (Dual-
Luciferase Reporter Assay System manual section 5 and subsection 6.A.).  These multiplicative 
changes to the luminescence ratios are presented as common additive offsets in the logarithmised 
values, and thus weighted averages of common 3′UTR types in different measurement days were 
used to normalise for differences between those days.
Further, while measurement days 1-0, 1-1, and 1-2 (measurement day abbreviations explained in 
Appendix A) had 1:11.8 control:reporter co-transfection molar ratios (consisting of a constant 10 
nanograms (ng) internal control plasmid co-transfected with a reporter plasmid mass which was 
length-proportionate to 100 ng of unaltered pGL4.73), measurement days after those used 
transfections done with a 1:10 co-transfection molar ratio with a constant 200 ng total co-
transfection mass, as recommended by the TurboFect ‘Transfection Reagent Considerations’ user 
guide (Thermo Scientific TurboFect Transfection Reagent protocol Table 1).  Co-transfection ratio 
differences between measurement days should give rise to multiplicative differences which can 
similarly be corrected for through logarithmised-value additive-offset day-adjustment. 
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Though (+SV40) was the nominal reference 3′UTR type, day-adjustment was based on all common 
3′UTR types instead of (+SV40) alone so as to lower the influence that any single replicate's 
variation had on the adjustment process.  Specifically, each common 3′UTR type contributed to 
each day's day-adjustment offset according to that 3′UTR type's widest confidence interval in all 
days being compared.
When multiple days were normalised relative to each other, to calculate relative additive offsets the 
same set of weights across days was used to make a weighted average of all arithmetic means of all 
common 3′UTR type samples for each day, those values being logarithmised measurement ratios as 
described above.  Sample means were used as estimates of the ‘true’ value represented by the 
normally-distributed replicate measurements.  Each weight was the minimum inverse-variance of 
that 3′UTR type's relative expression level estimate within those days, so that a 3′UTR type's 
estimate's low variance in one day could not impart that 3′UTR type high weighting for a day on 
which its estimate had high variance.
After day-adjustment, a single common offset was used to set the approximate expression of the 
nominal reference 3′UTR type (+SV40) to '0' (representing 100% expression) for more intuitive 
evaluation of other 3′UTR types as relative to it. 
5.7. Graphical representation of data points
Data points were charted as strip-chart scatterplots in R version 3.6.2, allowing display of all values 
without needing to calculate a single estimate for each 3′UTR type.  The R package ‘vipor’ (VIolin 
POints in R) (RDocumentation, ‘vipor package’) was used to implement quasirandom jitter so that 
nearby points were visually distinct without overlapping.
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6. Results and Discussion
6.1. Differing plasmid DNA degradation and the implementation of ‘batches’
For the first three measurement days (1-0, 1-1, 1-2), co-transfection plasmid mixtures were mixed 
on each transfection day (one transfection day per measurement day).  This was changed after failed
measurement days in which Firefly luciferase expression measurements were unusably low, 
unaffected by the assay substrate's condition (data not shown).  Upon testing, it was revealed that 
plasmids stored in different tubes were degrading at different rates, due to shearing when vortexing 
(Wu et al., 2009, Fig. 8) or storage conditions or otherwise, and in doing so displaying effective 
transfection efficiencies which were not representative of their measured concentrations (Fig. 7).
As NanoDrop concentration measurement cannot distinguish between degraded and undegraded 
DNA, one option considered was to make fresh plasmid preparations for each measurement day, 
exposing each plasmid type to the minimum possible time and vortexing before transfection.  To 
save time, a ‘batches’ approach was instead adopted in which groups of reporter plasmids and their 
internal control plasmid were prepared together, co-transfection mixtures made soon after plasmid 
preparation, and those same mixtures used in all measurement days for that batch.  The intention 
was that, even if different co-transfection mixtures underwent different degrees of degradation, the 
reporter and internal control plasmids in each mixture would undergo the same degree of 
degradation and maintain the same relative effective transfection efficiency.
As inaccuracies in both NanoDrop concentration measurement and human pipetting can introduce 
ratio-variation stochastic error, this approach of using the same mixture for multiple measurement 
days unfortunately limits the number of ratio-variation instances for each 3′UTR type to the number
of batches in which that 3′UTR type is measured, rather than every measurement day having a 
different error to contribute to averaged noise.  However, day-adjustment normalisation of 
measurement-day substrate-efficiency differences within batches becomes more reliable.
When using batch grouping, data point day-adjustment (subsection 5.6) between different batches 
requires those batches to share at least one 3′UTR type, rather than staggering 3′UTR type 
measurement as new types are added and thoroughly-tested types retired.  However, this can be 
bypassed through two measurement days for different batches being carried out in the same session 
with the same luciferase substrates and same co-transfection molar ratio, in which case day-
adjustment is unnecessary as the day is already the same.  This was done for measurement day 2-
2/3-1 to anchor batches 2 and 3 to each other, though there was no similar double measurement day 
to anchor batch 1 to batch 2 or 3.
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Figure 7.  DNA degradation of plasmids used in co-transfection, suspected to be due to vortex mixing.  100 ng DNA 
masses according to NanoDrop concentration measurements were subjected to electrophoresis, then the DNA band 
intensities of different plasmid isoforms (supercoiled, nicked, and linear (Tirabassi, n.d.; Oppenheim, 1981)) observed.  
The DNA ladder is Thermo Fisher Scientific's GeneRuler 1 kb DNA Ladder.
(a)
Sample lane 1 contains rarely-vortex-mixed undiluted purified pGL4.73 plasmid DNA (Fig. 4b).  It displays a strong 
supercoiled-plasmid band, a weak nicked-plasmid band, and no visible linear-plasmid band.  
Sample lane 2 contains pGL4.73 plasmid originally diluted from sample lane 1's source tube, frequently vortex-mixed for
use in co-transfections.  It displays a strong nicked-plasmid band, a medium-strength supercoiled band, and a weak 
linear-plasmid band.  
Sample lane 3 contains linear DNA derived from digesting plasmid DNA from sample lane 1's source tube with 
FastDigest XbaI and FastDigest SalI, then purifying with a NucleoSpin spincolumn.
Sample lane 4 contains DNA eluted in a second elution from the spincolumn of sample lane 3.  Sample lanes 3 and 4 
together show how the NanoDrop-measured DNA concentration of a second-elution eluate is untrustworthy, thought to be
due to a higher chaotropic salt concentration relative to DNA concentration, as reflected in a NanoDrop absorption ‘peak’
more resembling a diagonal line than a peak (data not shown).
(b) All samples are pGL4.13 plasmid DNA (Fig. 4a).  
Sample lanes 1 and 2 contain freshly-prepared plasmid from two different minipreps.  It shows strong supercoiled-
plasmid bands and weak nicked-plasmid bands.  Despite the NanoDrop-measured ostensibly equal masses, the two 
samples' band strengths are visibly different, thought to be due to different chaotropic salt proportions (as in (a) sample 
lane 4).  
Sample lane 3 contains rarely-vortex-mixed undiluted purified pGL4.13 plasmid, analogous to (a) sample lane 1.  It 
displays a weaker supercoiled-plasmid band and stronger nicked-plasmid band than samples lanes 1 or 2.  
Sample lane 4 contains pGL4.13 plasmid originally diluted from sample lane 3's DNA and frequently vortex-mixed for 
use in co-transfections, analogous to (a) sample lane 2.  It displays weak nicked- and linear-plasmid bands and no visible 
supercoiled band.
6.2. Statistical analysis
Readers wishing to carry out alternative statistical analysis can find all measurement data in 
Appendix D.
6.2.1. Initial intentions
Compared to Genetics, my Statistics foundation is much shallower.  It was initially imagined, being 
able to obtain an expression level estimate (mean) and confidence interval (Barde and Barde, 2012) 
for each measurements-replicate sample, that it would be possible to combine normalised 
measurements under different conditions to arrive at a single estimate and confidence interval for 
the true expression level which took into account all sample estimates and confidence intervals.  At 
the time, it was imagined that resultant estimates would have smaller confidence intervals for 
consistent contributing estimates (such as estimates within each other's confidence intervals) and 
wider confidence intervals for more divergent contributing estimates (such as estimates falling 
outside each other's confidence intervals).
The intention was to use 3-sigma (99.7%) confidence intervals, as a 95% confidence interval would 
be expected to exclude an estimated true parameter 1 in 20 times (compared to 3 in 1000 times), 
and this thesis project uses measurements from more than 20 3′UTR types.
In practice, first would have been obtained a single estimate and confidence interval per 3′UTR type
per measurement day, then per 3′UTR type per batch, and then finally only per 3′UTR type.
It was then planned, upon obtaining a single estimate and confidence interval for every 3′UTR 
type's relative expression level, to learn and carry out an appropriate statistical analysis method for 
numerically estimating how distant different parameters were likely to be from each other.  
Considerations planned to make sure to be taken into account or else explicitly acknowledged as 
problems were the unreliability of p-values (Cohen, 1994; Greenland et al., 2016) and the multiple 
comparisons problem.  For the unreliability of p-values there was curiosity about whether a 
Bayesian method could be used to directly report subjective likelihood ratios (Cohen, 1994; Kass 
and Raftery, 1995).  For the multiple comparisons problem the term ANOVA (ANalysis Of 
VAriance) had been previously encountered, said to compare all estimates to each other in a single 
operation.
These plans collapsed upon being unable to obtain a meaningful way of combining different 
estimates.
A sample mean represents two forms of bias, namely the distance of the sample mean from the 
sample's population mean and the distance of the sample's population mean from the true value to 
be measured.  The first bias originates from different measurement conditions within a replicate 
(such as slightly different delays when operating measuring equipment); the second bias originates 
from different measurement conditions between replicates (such as slightly different mixing ratios 
when mixing reporter and internal control plasmids for co-transfection).  Systematic contributors to 
bias can be partly corrected for by normalisation, while stochastic contributors can be partly 
corrected for by averaging.  When a sample has a small confidence interval, it represents that the 
within-replicate bias is low.
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Notably, for normally-distributed values such as that this thesis's logarithmised measurement ratios 
were intended to be, a sample's mean (and its distance from the sample's population mean) and its 
sample variance are independent (Geary, 1936; Knight, 2000, proposition 2.11)--the confidence 
interval is dependent only on the sample size and the sample's population variance.  However, the 
estimated population variance is still calculated from the sample variance, whether from averaging 
infinite sample variances which have undergone Bessel's correction to give unbiased estimates of a 
common population variance, or instead using a different correction for fewer sample variances 
(Eq. 1).
When calculating a final estimate from multiple sample estimates, weighting the sample estimates 
according to sample confidence interval decreases within-replicate bias while skewing between-
replicate bias, and using no weighting gives an unskewed between-replicate bias while letting low-
confidence samples introduce more within-replicate bias.  I do not currently know how to calculate 
what weighting minimises total bias, and have no leads on how to calculate the confidence interval 
of a final estimate when the contributing estimates have different confidence intervals.
At this point, the ANOVA method appeared the most ready tool to hand, being a frequently-used 
tool to handle data with different sources of variance--in this case, the between-replicate-
measurements variance, the between-measurement-days variance, and the between-batches 
variance.  However, ANOVA requires homogeneity of variance (homoscedasticity) as an 
assumption.  Predicting that the samples of logarithmised measurement-ratios, obtained through the 
same measurement procedure, would have the same variance (due to the within-replicate noise 
being of the same source in each case), it was thus sought to test the samples for homogeneity of 
variance, which if satisfactory would also allow calculation of samples' estimates' confidence 
intervals from estimated population variance and sample size alone, rather than depending on 
individual sample variances which were independent of their sample mean's distance from the 
population mean.
6.2.2. Insufficient evidence for homogeneity of samples' population variance
A chi-squared distribution scaled according to its degrees of freedom has a mean of 1, being the 
population variance of the standard normal distribution that gives rise to it.   If further scaled 
relative to a different number, it will instead appear as though it originated from a normal 
distribution with a population variance of that number.  Bessel-corrected sample variances of a 
constant sample size likewise take the form of a scaled chi-squared distribution (Knight, 2000, 
proposition 2.11) with an unbiased mean at the origin normal distribution's population variance, 
with one fewer degree of freedom than the sample size.
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Equation 1. Sample variance correction to use when averaging corrected sample variances of a normal 
distribution to estimate a common population variance, such that the mean square error of the estimate is 
minimised.  n is the number of measurements per sample ('sample size') and m is the number of samples. 
For infinite samples, this approaches Bessel's correction n/(n-1), giving an unbiased-but-loose estimator, 
the estimates of which can be averaged to an exact value.  For a single sample (in which case averaging is
not possible), this is n/(n+1), giving a tight-but-biased shrinkage estimator (Singh and Saxena, 2001, Eq. 
1.2 and 1.7).  For 116 samples of sample size 3, this is 3/(3 - 1 + (2/116)), equal to 58/39.  For 0 samples, 
this is undefined.
Sample variance correction = n
n−1+ 2
m
The 116 sample variances of sample size 3 were sorted and Bessel-corrected to form an empirical 
cumulative distribution function (CDF) and compared to the CDF of an ideal chi-squared 
distribution with 2 degrees of freedom, scaled according to the estimated population variance 
(~0.01192, equivalent to a standard deviation of ~1.27-fold when represented as an unlogarithmised
relative expression level; 3-sigma would be equivalent to ~2.05-fold) (Fig. 8).  However, the 
empirical CDF curve did not match the predicted scaled CDF, and instead more closely resembled a
predicted chi-squared distribution with only 1 degree of freedom.
Levene's test was also carried out, understood to be a typical homogeneity of variance test for 
before allowing an ANOVA, on all 123 samples (116 of sample size 3 and 7 of sample size 2).  The 
result was displayed as '.000', indicating to reject the null hypothesis of homogeneity of variance, 
consistent with the visual impression of the empirical CDF.  As further examples, the Levene's test 
significances for all (+SV40) samples, all Batch 2 samples, and all Batch 2 Day 1 samples were 
displayed as '.006', '.000', and '.001' respectively.
While Welch's ANOVA is an ANOVA that does not require homogeneity of variance, to my current 
knowledge it only exists as a One-Way version and not in the Three-Way form appropriate for 
analysis in this instance (to account for the contributing factors of 3′UTR type, measurement day, 
and batch).
As the samples could not be indicated to possess a common population variance, the subsection 5.6 
day-adjustment normalisation's inverse-variance weighting was carried out with population variance
estimates as estimated from each sample separately (Eq. 2).  
Aside from the mean square error, other estimators exist such as mean absolute error and maximum 
likelihood estimation which may have different advantages.  Minimisation of the mean square error 
was chosen with the intention that by definition this would minimise the variance, and thus the 
confidence interval, as though taken respective to the true parameter being estimated (Murphy, 
2012, subsection 6.4.4).
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Equation 2. Equation for each sample's estimate's inverse-variance.  One measurement in a sample is Xi, 
and the number of measurements in a sample ('sample size') is n.  As the measurements in each sample 
were planned to be normally-distributed, the 'true expression level' estimate is the mean of the sample 
measurements, for which the variance is the sample's population variance divided by the sample size 
(Wellmer, 1998; Murphy, 2012, Eq. 6.43).  As an assumption of common population variance could not 
be satisfactorily supported, each sample's population variance estimate uses the normal distribution 
sample variance correction for one sample only (Eq. 1).
estimate's inverse-variance ~= sample size
population variance estimate
= n
1
n+1∑i=1
n
( X i−X)
2
Lacking time in the remainder of the Master's degree duration for further statistics self-study, and at 
a loss as to how meaningful analysis of my results could be carried out, consultation was sought 
with University Lecturers Pekka Heino and Janne Ravantti.  The conclusion was to display the 
results in strip-chart scatterplot form, so as to include all data in a visually-intuitive way without 
carrying out numerical hypothesis-testing.  Confidence intervals or box plots were not used as the 
uncombined markings for each different 3- or 2-measurement sample for a 3′UTR type would have 
rendered the charts unreadable.
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Figure 8. Curve-comparison homogeneity of variance check in LibreOffice Calc.  116 samples all of 
sample size 3 were used.  n is sample size.  Bessel-correction is multiplication of a sample variance 
by n/(n-1) to obtain an unbiased estimate of population variance.  Sorted-and-scaled Bessel-corrected
sample variances as an empirical cumulative distribution function are compared to 1-degree-of-
freedom and 2-degrees-of-freedom scaled chi-squared distribution curves, charted in the form 
{f(x)}=CHISQDIST(1*{x}/0.01192,1,1) and {f(x)}=CHISQDIST(2*{x}/0.01192,2,1) respectively.  
The expectation was held that the samples' curve should most closely match the 2-degrees-of-
freedom curve (Knight, 2000, proposition 2.11) if the samples possess a common population 
variance (estimated as 0.01192); however, it does not.  
6.2.3. Insufficient evidence for samples being normally-distributed
Despite having intended that the logarithmised measurement ratios be normally-distributed, the 
inability to assume a common population variance casts doubt on this.
Residuals for all 123 samples were calculated by subtracting each sample's mean from its 
measurements, then in R a Shapiro-Wilk normality test carried out and a Q-Q plot drawn (Fig. 9).  
The Shapiro-Wilk result was displayed as '0.000000005978', indicating to reject the null hypothesis 
of a normal distribution, and the Q-Q plot appears normal in the middle while giving an impression 
of being too light-tailed, as of a Student's-t distribution.
The approximate symmetry of the samples' distribution bodes well for using the samples' means as 
expression value estimates, but the distribution not being normal bodes ill for methods using 
population variances estimated assuming normal distributions.  Unfortunately, I currently lack 
methods for making estimations based on non-normal distributions.
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Figure 9. Q-Q plot of sample residuals for normality testing, produced in R with qqnorm() and 
qqline().
6.3. All measurements in unadjusted and day-adjusted forms
Figure 10 displays the data points for all 3′UTR types tested in this thesis.  All raw and processed 
measurement values are recorded in Appendix D.
In the unadjusted data (Fig. 10a), a common offset can at a glance be observed between 
measurement days 2-1 and 2-2 (purple and orange circles), and between 3-1 and 3-2 (orange and 
green triangles).  After day-adjustment (Fig. 10b), these and other data points are instead clustered 
closely together, assisting comparison of relative protein expression.  Replicates' data points more 
distanced from others of the same 3′UTR type are overwhelmingly from measurement days 1-0, 1-
1, and 1-2, reflecting the less reliable nature of their different workflow (subsection 6.1).
3′UTR types (+SV40), +0lox-F(+SV40), and +mDNAJB6-1 are the only ones present in both 
Preparation Batch 2 (circles) and Preparation Batch 3 (triangles), and the closeness of their 
unadjusted points on Measurement Day 2-2/3-1 (orange circles and triangles) supports that no day-
adjustment is necessary when the measurement session, substrates, and co-transfection molar ratio 
are all the same.
In addition to flex-cassette and viral sequence testing (described in later subsections), 3′UTRs from 
twenty genes for anti-aggregation, aggregation (Chiti and Dobson, 2017), and neuron-survival 
proteins were tested both for evaluation as candidates for conditional knockup and to see whether 
any common aspect emerged that could shed light on neurodegeneration and possible treatment 
approaches.  However, all three groups exhibited expressions within the same overall range with no 
major distinction between observed expression levels.  
One noteworthy 3′UTR type was +mGDF11, which showed far lower expression than all other 
3′UTR sequences tested.  Upon checking, it was found that the NCBI reference sequence 
NM_010272.1 used for +mGDF11's primer design does not contain the expected polyadenylation 
signal, unlike the equivalent-at-the-time Ensembl Genome Browser reference sequence 
ENSMUST00000026408.6 which has a 3′UTR length of 2811 bp rather than 560 bp.  At this time 
of writing, NCBI displays the reference sequence NM_010272.2, which has a 3′UTR length of 4582
bp.  +mGDF11's low observed expression is thus predicted to be an artefact of its 3′UTR sequence 
being incomplete.
Most figures in later subsections show subset data from Figure 10b.
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6.4. Flex-cassette conditional knockup testing
6.4.1. Initial test
The one available example of in vivo flex-cassette conditional knockup was mouse GDNF (Fig. 3).  
An ideal in vitro comparison to emulate this would have been a ‘+flex-B+mGDNF’ and a ‘+1lox-
F+mGDNF’ 3′UTR types to reproduce the excision-flipping of the flex-cassette, but in the face of 
PCR difficulties these were not successfully constructed within the available timeframe.
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Figure 10. Full results, broken down into specific comparisons in later figures.  These are the measured effects on protein 
expression in HEK-293 cells of all 3′UTR types described in this thesis, grouped by category.  A relative expression of 0 is 
100%, 1 is 200%, 3 is 800%, -1 is 50%, et cetera. Preparation Batch indicates the batch of plasmids prepared and measured 
at the same time, and Measurement Day is the abbreviation for each day in {Batch}-{Batch's day} format, with 
measurement sessions 2-2 and 3-1 performed on the same day.  Total number of measurements/data points for each 3′UTR 
type is indicated as the suffix ‘_(n={measurement number})’.  (a) Raw-data logarithmised measurement ratios with no 
adjustment. (b) Logarithmised measurement ratios adjusted for measurement day as described in subsection 5.6.  All 
displayed data points are recorded in Appendix D, Table 7.  All measurement day and 3′UTR type abbreviations are listed 
and described in Appendix A.  
Initially, +mGDNF+60bp(+SV40) and (+SV40) were compared with +flex-F(+SV40) and +flex-
B(+SV40), and +1lox-F(+SV40) was constructed later together with other plasmids for more in-
depth investigation.  However, here the +1lox-F(+SV40) comparisons results can be shown first.
In Figure 11, the +mGDNF+60bp(+SV40) +1lox-F(+SV40) are examined to compare the 
expression from the GDNF 3′UTR to that of the excision-flipped (forward-orientation) bGHpA 
flex-cassette, if the sequence downstream of the flex-cassette is consistently cleaved away in 
cleavage-and-polyadenylation.  The effect of an upstream unflipped (backward-orientation) bGHpA
flex-cassette on the expressions of the (+SV40) and +mDNAJB6-3 3′UTR types is similarly 
displayed.
The forward-orientation (‘-F’) GDNF-comparison in vitro result (+1lox-F expression between 4- 
and 8-fold greater than for +mGDNF+60bp(+SV40)) is consistent with the in vivo result 
(heterozygous expression with Cre recombinase between 4- and 8-fold greater than for wild-type), 
keeping in mind that with binary-logarithmised values a distance of 1 equates to a 2-fold difference 
in expression.
By contrast, the backward-orientation (‘-B’) in vitro result (an approximate 8-fold drop in 
expression for both tested 3′UTR types) is wholly inconsistent with the in vivo result (heterozygous 
expression without Cre recombinase no lower than for wild-type).
The inability to fully reproduce the in vivo behaviour in this in vitro context warns of potential 
unreliability if wanting to use the same method for other testing.  To learn whether the bGHpA 
sequence or lox sites were responsible for this, more in-depth investigation was carried out.
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Figure 11.  Initial conditional knockup text.  These are the effects of an inserted upstream excision-
flipped flex-cassette (‘1lox-F’) or unflipped flex-cassette (‘flex-B’) on the 3′UTR following.  In this 
figure (unlike in Figure 12) the +1lox-F(+SV40) is only valid if replacement of the downstream 
3′UTR is assumed, as a ‘+1lox-F+mGDNF’ 3′UTR type could not be constructed in the necessary 
timeframe.  All measurement day and 3′UTR type abbreviations are listed and described in 
Appendix A.  
6.4.2. Readthrough-influence test
To investigate the bGHpA flex-cassette behaviour in vitro, the first underlying assumptions checked
were those about its respective behaviour with the bGHpA sequence in forward and backward 
orientation.  Namely, keeping the flanking lox sites identical for constant influence, does the 
forward-orientation flex-cassette reliably replace the expression of a downstream 3′UTR as 
intended, or is its cleavage-and-polyadenylation behaviour instead weak rather than strong (Chao et 
al., 1999)? Does the backward-orientation flex-cassette have zero cleavage-and-polyadenylation 
behaviour as intended, or does it instead replace the downstream 3′UTR?  In a readthrough-
influence test (Fig. 12), the downstream SV40 3′UTR was removed from +flex-F(+SV40) and 
+flex-B(+SV40) to test whether its influence was as intended negligible for the first and 
predominant for the second.  The SV40 3′UTR was likewise removed from 
+mGDNF+60bp(+SV40) to test whether it was affecting measured expression, possible if the 
GDNF 3′UTR cleavage-and-polyadenylation behaviour were weak rather than strong.
Separately, most inserted 3′UTR sequences taken from mouse genes were PCRed starting from 
immediately after a stop-codon and ending at the point corresponding an mRNA transcript's 
cleavage-and-polyadenylation site:  however, in mRNA transcription a longer transcript is first 
transcribed, then cleaved at the cleavage-and-polyadenylation site.  The cleavage and 
polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) protein complexes 
cooperate to do this, of which CPSF binds upstream at the AAUAAA-like polyadenylation signal 
while CstF binds to downstream GU/U-rich sequence elements.  During the binding-and-cleavage 
process, approximately 200 nucleotides can be transcribed (Chao et al., 1999).
Unknowing whether the pGL4.73 template plasmid's sequence was sufficiently GU/U-rich for 
reliable cleavage-and-polyadenylation to occur, and whether transcribed native downstream 
sequences had other expression-relevant effects prior to cleavage, three 3′UTR types were 
reproduced with extensions of between 500bp and 1kb from downstream of the cleavage-and-
polyadenylation site gene template.  Plasmid constructs created after this point in time were 
similarly extended, with the aim of preserving the native cleavage-and-polyadenylation context.
For all forward-orientation 3′UTR types compared to extended versions, the data point spread 
within the unextended 3′UTR type exceeded the distance between the unextended and extended 
3′UTR types.
For the backward-orientation flex-cassette alone, the absence of the downstream 3′UTR produced a 
drop in expression of 4-fold or greater, suggesting that the majority of expression originates from 
that downstream 3′UTR, as intended.  That said, this expression level (2−6 of (+SV40)) was still 8-
fold greater than the lowest expression observed (+mGDF11, discussed in subsection 6.3, with 
expression 2−9 of (+SV40)), which bears further investigation such as through RNA sequencing of 
generated transcripts. 
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Figure 12. Readthrough-influence overall test.  These are the effects on protein expression of a 
3′UTR's downstream sequence.  The backwards-orientation flex-B sequence, intended to be read 
through without signalling transcript cleavage, suffers an approximately 8-fold drop when the 
(+SV40) 3′UTR following it is removed.  The mGDNF and flex-F sequence, which having 
forwards-orientation are intended to signal transcript cleavage, have a small change in expression if 
any after the same excision.  The addition of genomic DNA following the transcript cleavage site for
mDNAJB6-1, mAPP, and mSNCA results in a small change in expression if any.  Together this 
suggests a low influence of downstream sequences on forward-direction 3′UTRs.  All measurement 
day and 3′UTR type abbreviations are listed and described in Appendix A.  
6.4.3. Lox-influence test
Having established that 3′UTR conditional replacement largely works as intended, the other aspect 
to investigate was whether the presence of the lox sites was responsible for the lower protein 
expression from +flex-B(+SV40), perhaps through hairpin formation in the plasmid.  To do this, 
bGHpA in backward- and forward-orientation was tested with a loxP and lox5171 site on each side 
(‘flex’), with the outermost lox site removed from each side (‘1lox’), and with all lox sites removed 
(‘0lox’).
Kakoki et al.'s work (Kakoki et al., 2004) does suggest that a loxP site can lower expression, though
as their work was done through genomic alteration and the purpose of this test was to investigate a 
discrepancy between genomic effects and plasmid effects, this is of limited relevance unless a 
‘+flex-B+mGDNF’ 3′UTR type did not display a lower expression than a ‘+mGDNF’ 3′UTR type.
As shown in Figure 13, removal of all lox sites flanking the backwards-orientation bGHpA 
sequence fully restored (+SV40) expression, indicating that the lox sites—an intrinsic part of using 
a flex-cassette for conditional knockup—were responsible for the lowered expression levels 
observed.  The expression from the forward-orientation bGHpA was also improved by the removal 
of lox sites, though to a lesser degree—perhaps due to the lox sites being closer to the end of the 
produced mRNA transcript than in backward-orientation cases for which the downstream SV40 
3′UTR is not cleaved away.  As the GDNF 3′UTR is over 2 kb long (see Appendix A), this 
hypothesis bears further investigation:  for instance, through the comparison of lox sites inserted at 
different positions in a long 3′UTR sequence.
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6.5. Comparison of different co-transfection ratios
Promega's dual-luciferase assay manual warns that co-transfected plasmids with identical promoters
can suffer from trans effects, and recommends a control:reporter co-transfection molar ratio 
between 1:10 and 1:50 (Dual-Luciferase Reporter Assay System manual subsection 3.B.).  pGL4.13
and pGL4.73 both use the SV40 enhancer and promoter, and while measurement days 1-0, 1-1, and 
1-2 were conducted with a 1:11.8 control:reporter ratio, all other measurement days were conducted
with a 1:10 ratio, right at the edge of the recommended range.
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Figure 13. Lox-influence conditional knockup test.  These data points are bGHpA in the backward- 
and forward-orientation with the flex-cassette flanking loxP and lox5171 sites progressively stripped
away.  (+SV40) is side-by-side with +flex-B(+SV40), showing that the backward-orientation flex-
cassette addition decreases expression approximately 8-fold; stepwise removal of all lox sites 
(+1lox-B(+SV40), +0lox-B(+SV40)) then shows how expression can be completely restored while 
the backward-orientation bGHpA sequence remains.  Expression from forward-orientation bGHpA 
(+flex-F(+SV40), +1lox-F(+SV40), +0lox-F(+SV40)) also shows improvement.  All measurement 
day and 3′UTR type abbreviations are listed and described in Appendix A.  
For these 1:11.8 measurement days, +mAPP seemed to display a high expression relative to 
(+SV40) (Fig. 14), yet a near-equal expression to (+SV40) in later measurements, including for 
+mAPP-extended.  To check this, (+SV40) and +mAPP were first tested in adjacently-measured 
triplets with control:reporter co-transfection molar ratios of 1:10 and 1:25 as part of measurement 
day 3-2 (Fig. 14).  
As the +mAPP expression appeared a little higher than the (+SV40) for the 1:25 co-transfections, a 
more thorough comparison was carried out on measurement day 4-0 with ratios of 1:10, 1:20, 1:40, 
1:80, and 1:60.  Measurement ratios were scaled according to each co-transfection ratio and 
compared in a single chart (Fig. 15).  This showed no divergent-expression trend for different co-
transfection ratios, and so it was concluded that initially high +mAPP relative expression was due to
differing plasmid degradation or other initial unreliability, rather than due to the co-transfection 
ratio.
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Figure 14. A preliminary test of the effect of different co-transfection ratios.  For a 1:10 
control:reporter plasmid ratio, (+SV40) and +mAPP presented similar expression levels, whereas for
a 1:25 ratio the expression level of +mAPP appeared a little higher than that of (+SV40).  All 
measurement day and 3′UTR type abbreviations are listed and described in Appendix A.
6.6. Candidates for bGHpA flex-cassette conditional knockup
Lox-site-present in vitro behaviour was seemingly inconsistent with in vivo behaviour, but as the 
+1lox-F expression relative to +mGDNF+60bp(+SV40) was seemingly consistent with in vivo 
mouse kidney GDNF conditional knockup results (subsection 6.4.1), in vivo mouse models could in
future be constructed to examine whether in vivo forward-orientation predictions are reliable.
For the genomic 3′UTRs used in this project, conditional knockup candidates are those for which 
the expression level was measured to be lower than that of +1lox-F, namely the 3′UTRs of 
+mDNAJB6-3, +mPARK2-1, +mMME, and +mDNAJB6-1 (Fig. 16).  Of these +mPARK2-1 
belonged to the neuron survival gene group and the others to the anti-aggregation gene group, and 
+mDNAJB6-1 displayed the lowest expression relative to +1lox-F.
For mouse DnaJ heat shock protein family (Hsp40) member B6 (DNAJB6) in particular, transcript-
specific qPCR primers should be used when measuring in vivo mRNA levels to avoid confusion 
with expression from other transcripts' 3′UTRs.
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Figure 15. A further test of the effect of different co-transfection ratios.  In a small batch solely for ratio-
testing, plasmids (+SV40) and +mAPP were compared to each other at control:reporter co-transfection 
ratios of 1:10, 1:20, 1:40, 1:80, and 1:160, and the displayed results were scaled according to the ratio 
used.  All displayed results were similar, with no apparent expression difference emerging between 
(+SV40) and +mAPP at more extreme co-transfection ratios.  Means and 95% confidence intervals were 
calculated from log2(Renilla/Firefly) ratios as 1.96*{Sample standard deviation}/sqrt({Sample size}), 
with {Sample size}=3 for all ten samples, and charted in LibreOffice Calc.  All measurement day and 
3′UTR type abbreviations are listed and described in Appendix A.
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Figure 16. Candidates for flex-cassette conditional knockup.  These are the measured 3′UTR types 
with potentially-lower expression than +1lox-F, the 3′UTR type representing an excision-flipped 
bGHpA flex-cassette inserted upstream of a native 3′UTR.  The four candidate 3′UTR types are 
arranged in approximate order of decreasing expression, and though +mDNAJB6-3 includes 
measured relative expressions close to and above those of +1lox-F, these are from the 1-0/1-1/1-2 
measurement days viewed as less reliable than the later measurement days (subsections 6.1 and 6.3).
All measurement day and 3′UTR type abbreviations are listed and described in Appendix A.  
6.7. Alternatives to bGHpA for flex-cassette 3′UTR replacement
While 3′UTR types with lower expression than +1lox-F represent candidates for conditional 
knockup with the bGHpA flex-cassette, 3′UTR types with higher expression than +0lox-F instead 
represent candidates to use in a flex-cassette as an alternative 3′UTR to bGHpA.
A significant factor however when considering bGHpA replacement is that of 3′UTR length, in that 
viral vectors and other DNA delivery methods typically have limited sequence capacity. In practice, 
the longer the replacement 3′UTR, the less capacity is available for protein coding sequences or 
gene control elements.  While mouse model creation is not limited by this, some thought could still 
be spent on vector requirements for eventual adult treatment.
Though the bGHpA sequence has a length of only 297 bp, candidate mouse 3′UTRs in this project 
were those of +mSNCA (556 bp), +mDNAJB6-2 (671 bp), +mAPP (895 bp), +mACTB-extended 
(683+530 bp), and +mDNAJC6 (2226 bp), all more than twice the length of bGHpA (Fig. 17; 
Appendix A).
The (+SV40) (256 bp) and +WPRE+bGH (1170 bp) sequences also showed comparatively high 
expressions in this assay, but viral-origin sequences are at risk of undergoing eventual epigenetic 
silencing in mammalian cells, which conflicts with the desired purpose of long-term medical 
treatment, and WPRE which showed the highest expression in the form of +WPRE+bGH is 
unusable in some cell types (Klein et al., 2006).
(+SV40) though short in length is also unusable as a flex-cassette candidate due to being the shared 
3′UTR region of two opposite-direction SV40 genes, SV40gp5 and SV40gs1.  The pGL4.73 
(+SV40) 256 bp 3′UTR consists of 24 bp SV40-unrelated sequence, 56 bp forward-orientation 
SV40gp5 coding sequence and stop codon, 97 bp shared-3′UTR-region in the SV40gp5 direction, 
69 bp backward-orientation SV40gs1 coding sequence and stop codon, and 10 bp SV40-unrelated 
sequence (according to NCBI's reference sequence NC_001669.1 (Fig. 18)).  While a flex-cassette 
replacement 3′UTR should cause cleavage-and-polyadenylation in the forward-orientation and not 
in the backward-orientation, (+SV40) thus does so for both orientations.
Notably, the 145 bp SV40 3′UTR sequence successfully used by Kakoki et al. (Kakoki et al., 2004) 
is in the opposite orientation and shares 130 bp of overlap with the pGL4.73 (+SV40) 3′UTR, 
consisting of 153 bp forward-orientation SV40gs1 coding sequence and stop codon, together with 
61 bp shared-3′UTR-region in the SV40gs1 direction.  While not containing the full shared-3′UTR-
region, the Kakoki SV40 3′UTR still contains SV40gp5's polyadenylation signal and one of 
SV40gs1's two; all three polyadenylation signals are closer to the stop codon of the opposite 
direction from them than to their same-direction stop codon, and so preventing cleavage-and-
polyadenylation through sequence truncation appears infeasible. 
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Figure 18. NCBI SV40 3′UTR context, a screenshot from 
https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=23950 .  This is a section of the complete SV40 
genome in NCBI, accession number NC_001669.1, that shows the opposite-directions SV40gp5 and SV40gs1 shared 
3′UTR region (the 222 bp region from base 2,538 through base 2,759) used in plasmid pGL4.73.
Figure 17. Flex-cassette alternatives to bGHpA for 3′UTR replacement.  These are the 3′UTR types 
with potentially-higher expression than +0lox-F, the 3′UTR type which is forward-orientation 
bGHpA.  The candidate 3′UTR types are arranged in approximate order of increasing expression.  
All measurement day and 3′UTR type abbreviations are listed and described in Appendix A.  
6.8. Possible workflow improvements for future experiments
If further in vitro experiments were carried out prior to or in parallel with in vivo comparisons, there
are a number of changes, additions or deeper investigations that could be recommended.
6.8.1. Mouse cell line
In the current workflow, mouse 3′UTRs were tested in the human embryonic kidney cell line HEK-
293, for the reasons that HEK-293 was on-hand, grew quickly, and had good transfection efficiency.
Mouse 3′UTRs were used with in vivo mouse models in mind, but for more assured emulation of 
the native environment's RNA regulation a mouse cell line should be used instead.  Alternatively, 
the microRNA expression profile of a non-mouse cell line used could be compared directly to the 
microRNA expression profile of the intended-treatment-target mouse cell type, particularly paying 
attention to microRNAs with binding sites present in the affected sequences, perhaps as indicated 
by TargetScan Mouse ( http://www.targetscan.org/mmu_71/ ).
Further, while immortalised cell lines are always—through aneuploidy, mutation, or otherwise—
very different in behaviour from their original cell types, where upregulation is being considered in 
the context of treatment for neurodegeneration in brain cells, use of a brain cell line could closer 
approach the environment of interest.  This is particularly in light of the different degrees of 
upregulation derived from bGHpA flex-cassette knockup of GDNF in mouse kidney versus striatum
(Fig. 3), since microRNA expression varies according to cell type (Shivdasani, 2006).  For example,
the Neuro-2a cell line originates from mouse neuroblast cells.  Alternatively, several different 
mouse or mouse and human cell lines of differing origin could be used to estimate the influence of 
cell type on protein expression for each 3′UTR.
Further still, in the current workflow some 3′UTRs were tested which have no homologous 3′UTR 
sequence in the homologous human gene.  As an example, for the mouse DNAJB6 gene only the 
3′UTR for isoform c (‘DNAJB6-2’, reference sequence NM_011847.4) is homologous to a human 
DNAJB6 3′UTR, that of isoform b (reference sequence NM_005494.2):  574/698 identities, 
according to NCBI's Align Sequences Nucleotide BLAST blastn algorithm 
( https://blast.ncbi.nlm.nih.gov/Blast.cgi ).  If testing for the sake of future human medical treatment
rather than only as proof-of-concept, mouse genomic 3′UTR types tested could be limited to those 
with human homologues.  While the mouse 3′UTR types were tested in mouse cell line contexts, 
their human homologues could be tested in human cell line contexts, ideally both cell lines being of 
the same intended-treatment-target cell type.
 
6.8.2. Plasmid condition and concentration measurement
Though plasmid degradation was observed (subsection 6.1) and guessed to be caused by vortexing, 
this was not tested further.  Vortexing of different aliquots of the same plasmid at different speeds 
and for different lengths of time could be carried out to determine whether this can in fact produce 
significant plasmid nicking and fragmentation, and if so what limits on vortex-mixing would 
acceptably mitigate this.
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Another matter potentially able to affect plasmid condition is that of the elution buffer used.  As 
noted in Materials and Methods, extracted plasmids were stored in and diluted with sterile water 
rather than the plasmid extraction kit's elution buffer.  This was to ensure a plentiful supply for 
dilutions, as well as motivated by observing no immediate problems with NanoDrop-measured 
elution efficiency or effective transfection efficiency.  However, irreversible structural changes to 
DNA diluted in the absence of NaCl have been reported (Nakayama et al., 2016), and so this is 
another hypothetical contributor to the observed degradation.  This could likewise be tested by 
comparison of whether elution and dilution in elution buffer instead of sterile water can mitigate 
any repeatable degradation observed.
Finally, in the same gel in which degradation was observed (Fig. 7), the unreliability of NanoDrop-
measured elution concentrations is displayed, which could skew intended co-transfection ratios.  If 
inaccurate concentration measurements are due to chaotropic salt interference, then more accurate 
measurements might be obtainable from a Qubit fluorometer, which measures DNA-bound dye 
instead of 260 nanometer UV absorbance.
It could also be tested what concentrations a Qubit fluorometer reports for degraded DNA.  If 
degradation consistently reduced DNA to unmeasured free nucleotides, rather than to normally-
measured small fragments, then Qubit concentration measurement could be used immediately 
before co-transfection.  This would allow preparation of correct-ratio co-transfection mixtures even 
from partially-degraded plasmid preparations, rather than requiring the preparation of mixes for all 
of a batch's measurement days immediately after plasmid extraction.
Alternatively, several mixes with different stochastic pipetting errors could be simultaneously 
prepared for each 3′UTR immediately after plasmid extraction, to reduce pipetting error influence 
on a  3′UTR type measured in only one batch.
6.8.3. RNA transcript sequence verification
Noted in subsection 6.4.2, the +flex-B(no_SV40) 3′UTR type showed an expression level much 
higher than that of +mGDF11, even though +flex-B(no_SV40) had been thought to be the least 
viable of all 3′UTR types tested.  RNA sequencing would indicate what RNA transcripts are being 
produced from these two 3′UTR types, offering clues as to why one's relative expression is higher 
than the other (such as undesired cleavage-and-polyadenylation within the backward-orientation 
flex-cassette, which might then be preventable).
More generally, this could reveal for all measured 3′UTR types any undesired downstream plasmid 
sequence present in a polyadenylated mRNA transcript, such as when a reference sequence has 
included an insufficient length of a genomic 3′UTR.
In practice, Northern blotting with a probe specific to the Renilla luciferase coding sequence could 
be a less costly approach to check all tested 3′UTR types for surprising transcript lengths, prior to 
more in-depth investigation.
6.8.4. Flex-cassette internal sequence
As described in subsection 6.7, other sequences might offer more reliable results in a gene knockup 
flex-cassette than bGHpA.  A choice of different complete 3′UTRs would further allow fine 
adjustment when a specific new expression level is desired.  
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Other than influencing protein expression levels through the recruitment of proteins which affect 
mRNA stability, sequences in the 3′UTR can also exert different forms of posttranscriptional control
by recruiting proteins with other roles, such as intra-cell localisation and mRNA-dependent protein-
protein interactions (Tushev et al., 2018; Mayr, 2019).  There are even reports of 3′UTRs 
responsible for transcriptional silencing or enhancing of their own genes (Gomez-Benito et al., 
2011; Jash et al., 2012).  In order to modify only protein expression levels and not protein 
behaviour, 3′UTR modifications would need to only affect sequences which influence mRNA 
stability.
A way to achieve the same flexibility while meeting this requirement could instead be the use of 
multiple mRNA-half-life-increasing sequences, such as a cytoplasmic polyadenylation element or 
WPRE sequence, to impart a scalable incremental expression increase.  This would preserve 
microRNA cell-type-specific regulation, as well as any sequences which affect protein behaviour 
outside mRNA stability.
6.8.5. Statistical analysis method
In this project, data-points were presented directly in strip-chart scatterplots in lieu of conducting a 
numerical analysis.  It can be speculated that there should be a way to meaningfully analyse the 
recorded measurements, and if so then this would be a preferable method for future studies.  
It would not be appropriate to redesign the experimental procedures in order to improve estimation 
simplicity by narrowing data collection to a single set of conditions (such as carrying out 
measurements for only one large co-transfected sample on a single measurement day).  This would 
not remove the bias from stochastic errors in experiment preparation, and instead would remove 
points of reference for identifying and partly correcting for such bias.  Further, carrying out small 
lots of measurements on different days scales better for larger amounts of data:  each small lot of 
measurements benefits from assay substrates in approximately the same condition, as well as the 
full concentration of the experimenter.  For a single large lot of measurements, the first samples 
would have fresh assay substrates and a well-rested experimenter, but the last samples would 
instead have less-fresh substrates and a fatigued experimenter more prone to careless errors.
Though logarithmisation of measurement ratios appears appropriate for photomultiplier tube values,
this relies on an assumption of normally-distributed measurement values after logarithmisation, 
which bears further consideration.  Normality testing of logarithmised measurement ratio sample 
residuals (subsection 6.2.3) suggested that the residuals were not normally-distributed, but the 
implications of this are not clear unless first determining whether the residuals of normal 
distributions with different means are expected to be normally-distributed when outside the context 
of a linear regression analysis.  The inability to assume that samples possessed a common 
population variance (subsection 6.2.2) is similarly concerning.
If recorded measurements are of different distributions from those expected, their actual properties 
must be learned for those expectations to be adjusted and the data appropriately handled.  If 
recorded measurements are instead indeed of the expected distributions, then analysis methods 
adequate to conclude this are desirable.
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7. Conclusions
The largest contribution of this project has been a refining of the workflow used, namely the 
identification of problematic areas and the development of ways to address them, as well as the 
determination of future areas that could be focused on to answer remaining questions.  That said, 
the overall conclusion for the specific results obtained is that they are insufficiently conclusive and 
so require further studies.
In comparing different genomic 3′UTRs to each other in a known environment, no overarching 
trends in the gene categories focused on were evident.
If the in vivo human embryonic kidney cell line results had been wholly consistent with the in vivo 
mouse kidney GDNF conditional knockup results, then it would have been a point in favour of the 
reliability of this in vitro method for predicting the in vivo effects of 3′UTR modification.  Even so, 
further in vivo comparisons would have been appropriate in case that consistency had been a rarely-
occurring coincidence.  As there was only partial consistency (subsection 6.4.1), the impression 
obtained is instead one of mixed hope and doubt.
For the impression which gave hope, that hope can be put to the test through more in vivo mouse 
models for comparison, using several genes and tissues, while also expanding the in vitro tests to 
other cell lines.
For the impression which gave doubt, that doubt can be put to the test through either a bottom-up 
approach, a top-down approach, or ideally both.  The bottom-up approach is to test the effect of lox 
sites on protein expression according to their distance from the 3′UTR's end.  The top-down 
approach is to further pursue the creation of a ‘+flex-B+mGDNF’ 3′UTR type despite the long 
sequence length, perhaps through long multiple fusion of PCR products (Shevchuk et al., 2004), 
and see whether its expression matches that of a ‘+mGDNF’ 3′UTR type.  Otherwise, if different in 
vivo results consistently matched in vitro results for identical 3′UTR sequences, the mouse GDNF 
instance could be temporarily treated as a rare inconsistency until further investigation were 
possible.
Other than these approaches for testing whether this in vitro method is usably predictive of in vivo 
results, there remain a number of avenues of possible workflow improvement (subsection 6.8).  
Even if it were instead not predictive of in vivo results, this work could perhaps still be of use in 
improvement of in vitro industrial protein production.
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9. Appendices
9.1. Appendix A:  Measurement day and 3′UTR type abbreviations and 
identities
Table 3 records measurement day abbreviations and Table 4 3′UTR abbreviations.
Table 3.  Measurement day abbreviations, according to which measurement of which group (‘batch’) was or were 
measured in each day.
Day abbreviation Date Description
1-0 2017-08-10 Protocol test with only a few Batch 1 plasmids
1-1 2017-09-05 Batch 1 (full), Day 1
1-2 2017-09-27 Batch 1, Day 2
1-3 2018-09-03 Batch 1, Day 3
2-1 2018-09-11 Batch 2, Day 1
2-2/3-1 2018-09-17 {Batch 2, Day 2} and {Batch 3, Day 1} (same substrates 
used)
3-2 2018-10-10 Batch 3, Day 2
4-0 2018-11-19 Batch 4, Co-transfection molar ratio testing only
Table 4.  3′UTR abbreviations and their associated information, grouped by identity type.  Sequence lengths use (+#) to 
separately indicate downstream (+SV40) and genomic DNA downstream of a gene's cleavage-and-polyadenylation site, 
and do not take into account all restriction site lengths; see Appendix C for the primer sequences used.  Reference 
sequences are in the form of plasmid name, Appendix reference, NCBI accession number, or Ensembl Genome Browser
stable identifier.
3′UTR abbreviation Reference sequence
Sequence
length
(base
pairs)
Source identity
Viral sequences
(+SV40) pGL4.73 256
simian vacuolating virus 40
3′UTR, the default 3′UTR in
the Promega dual-luciferase
reporter assay plasmids, used
here as a control
+WPRE+hGH (see Appendix B) 1170
human growth hormone 1
3′UTR, here preceded by the
Woodchuck Hepatitis Virus
Posttranscriptional Regulatory
Element
Flex-cassette testing
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+0lox-F(+SV40)
(see Appendix B),
pGL4.73
297(+256)
bovine growth hormone 3′UTR
(forward direction), followed
by (+SV40)
+1lox-F(+SV40)
(see Appendix B),
pGL4.73
483(+256)
bovine growth hormone 3′UTR
(forward direction), with loxP
and lox5171 site, followed by
(+SV40)
+flex-F(+SV40)
(see Appendix B),
pGL4.73
622(+256)
bovine growth hormone 3′UTR
(forward direction), with loxP
and lox5171 sites, followed by
(+SV40)
+flex-F(no SV40) (see Appendix B) 622
bovine growth hormone 3′UTR
(forward direction), with loxP
and lox5171 sites
+0lox-B(+SV40)
(see Appendix B),
pGL4.73
297(+256)
bovine growth hormone 3′UTR
(backward direction), followed
by (+SV40)
+1lox-B(+SV40)
(see Appendix B),
pGL4.73
483(+256)
bovine growth hormone 3′UTR
(backward direction), with loxP
and lox5171 site, followed by
(+SV40)
+flex-B(+SV40)
(see Appendix B),
pGL4.73
622(+256)
bovine growth hormone 3′UTR
(backward direction), with loxP
and lox5171 sites, followed by
(+SV40)
+flex-B(no SV40) (see Appendix B) 622
bovine growth hormone 3′UTR
(backward direction), with loxP
and lox5171 sites
+flex-B+mDNAJB6-3
(see Appendix B),
(same as DNAJB6-3)
716
bovine growth hormone 3′UTR
(backward direction), with loxP
and lox5171 sites, followed by
+mDNAJB6-3
Anti-aggregation
+mDNAJB6-3 NM_001037941.3 89(+0)
mouse DnaJ heat shock protein
family (Hsp40) member B6,
isoform b 3′UTR
+mDNAJB6-2 NM_011847.4 671(+0)
mouse DnaJ heat shock protein
family (Hsp40) member B6,
isoform c 3′UTR 
+mDNAJB6-1 NM_001037940.4 1365(+0)
mouse DnaJ heat shock protein
family (Hsp40) member B6,
isoform a 3′UTR
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+mDNAJB6-1-extended
ENSMUST00000008733.
14
1365+571
mouse DnaJ heat shock protein
family (Hsp40) member B6,
isoform a 3′UTR and the
following 571 bp
+mDNAJC6 NM_198412.2 2226(+0)
mouse DnaJ heat shock protein
family (Hsp40) member C6 
+mHSPA1A NM_010479.2 641(+0)
mouse heat shock protein 1A
3′UTR
+mMITF NM_001113198.1 3183(+0)
mouse melanogenesis
associated transcription factor
3′UTR
+mMME NM_001289463.1 3381(+0)
mouse membrane metallo
endopeptidase 3′UTR
+mPCSK1N NM_013892.3 1307(+0)
mouse proprotein convertase
subtilisin/kexin type 1 inhibitor
3′UTR
+mSCG5 NM_009162.3 488(+0) mouse secretogranin V 3′UTR
Aggregation proteins
+mAPP NM_007471.3 895(+0)
mouse amyloid beta (A4)
precursor protein 3′UTR
+mAPP-extended
ENSMUST00000005406.
11
898+998
mouse amyloid beta (A4)
precursor protein 3′UTR and
the following 998 bp
+mITM2B NM_008410.2 827(+0)
mouse integral membrane
protein 2B 3′UTR (an
aggregation protein according
to Garringer et al., 2017)
+mSNCA NM_001042451.2 556(+0) mouse synuclein, alpha 3′UTR
+mSNCA-extended
ENSMUST00000114268.
4
550+972
mouse synuclein, alpha 3′UTR
and the following 972 bp
+mIAPP-extended
ENSMUST00000041993.
2
473+969
mouse islet amyloid
polypeptide 3′UTR and the
following 969 bp
+mPRNP-extended
ENSMUST00000091288.
12
1235+716
mouse prion protein 3′UTR and
the following 716 bp
+mACTB-extended
ENSMUST00000100497.
10
683+530
mouse actin, beta 3′UTR and
the following 530 bp
+mSOD1-extended
ENSMUST00000023707.
9
65+594
mouse superoxide dismutase 1,
soluble 3′UTR and the
following 594 bp
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+mTRP53-extended
ENSMUST00000171247.
7
564+523
mouse transformation related
protein 53 3′UTR and the
following 523bp
Neuron survival
+mGDF11 NM_010272.1 560(+0)
mouse growth differentiation
factor 11 3′UTR
+mGDNF+60bp(+SV40) NM_010275.3, pGL4.73
2748+60
(+256)
mouse glial cell line derived
neurotrophic factor 3′UTR,
followed by (+SV40)
+mGDNF+60bp(no
SV40)
NM_010275.3 2748+60
mouse glial cell line derived
neurotrophic factor 3′UTR,
followed by (+SV40)
+mPARK2-1 NM_016694.4 1713(+0)
mouse E3 ubiquitin-protein
ligase parkin, isoform 1 3′UTR
9.2. Appendix B:  Non-genomic template sequences
9.2.1. Flex-cassette template
Flex-cassette (reverse orientation) (cloned into pUC57)
 loxP site – Underlined
 lox5171 site – Underlined italics
 bovine growth hormone 3′UTR in inverse orientation – Bold
 AATAAA polyadenylation signal in inverse orientation - Bold highlighted
GGCCGCGAGCTAGATCTAGAATAACTTCGTATAGCATACATTATACGAAGTTATGGGTCGATGGTG
AGATCTGGACTAGAGGGTCGATGGTGATGCTTGGATAACTTCGTATAGTACACATTATACGAAGTT
ATCGGATCCCAGTGTGGTGGTACTCGAGGTCGACTCTAGAGGATCGAGCCCCAGCTGGTTCTTTCC
GCCTCAGAAGCCATAGAGCCCACCGCATCCCCAGCATGCCTGCTATTGTCTTCCCAATCCTCCCCC
TTGCTGTCCTGCCCCACCCCACCCCCCAGAATAGAATGACACCTACTCAGACAATGCGATGCAATT
TCCTCATTTTATTAGGAAAGGACAGTGGGAGTGGCACCTTCCAGGGTCAAGGAAGGCACGGGGGAG
GGGCAAACAACAGATGGCTGGCAACTAGAAGGCACAGTCGAGGCTGATCAGCGAGCTCTAGAGAAT
TGATCCCGAATTCGATAACTTCGTATAATGTATGCTATACGAAGTTATGGGTCGATGGTGATGCAT
GGCAATTCGGGTCGATGGTGAACTTGGCCCTACTAAATAACTTCGTATAATGTGTACTATACGAAG
TTATAAGCTCTAGACTAGATAATCCTGCA
Orientations:
-->loxP>-->lox5171>--<bGHpA<--<loxP<--<lox5171<--
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9.2.2. WPRE+hGH template
 WPRE sequence – Underlined
 hGH 3′UTR sequence – Bold underlined
GTACAAGTAAAGCGGCCGCACTCGAGATATCAAGCTTATCGATAATCAACCTCTGGATTACAAAAT
TTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTT
AATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTG
GTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTT
TGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGC
TTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGC
TCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTTGGCTGCT
CGCCTATGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCC
AGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCC
TCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGAGCGCTGCTCGAGAGATC
TACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTG
CCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAAT
ATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGC
GGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCC
TGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGG
CTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAAC
TCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACT
GCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCG
9.3. Appendix C:  Primers used
Table 5 records all primers used in this project.
Table 5. Sequencing and PCR primers used for this thesis's plasmids.  Upper-case letters refer to annealing sequences 
while lower-case letters refer to added restriction sites and their AT-rich 6-nucleotide leading sequences.  Restriction 
sites are indicated in the names where present, and F and R are used for Forward and Reverse-complement primers 
respectively; the no_SV40 primers are ordered with the R first because their PCR product is everything outside the 
SV40 3′UTR, with the two AscI restriction sites ligated to make a circular plasmid.
Sequencing primers
pGL4.73_seq_F ACATCAAGAGCTTCGTGGAG
pGL4.73_seq_R 
(anneals within (+SV40))
CAAACTCATCAATGTATCTTATC
pGL4.73_seq_R2 
(anneals after SalI site)
GAAGACAGTCATAAGTGCGG
PCR primers
Viral sequences
WPRE_NheI_F aataatgctagcGTACAAGTAAAGCGGCCGCAC
WPRE_bGHpA_SalI_R aataatgtcgaCGGTCCGCACGTGGTTAC
no-SV40_AscI_R attattggcgcGCCGCCCCGACTC
no-SV40_AscI_F attattggcgcgccGATAAGGATCCGTCGACC
Flex-cassette testing
bGHpA_0lox_MluI_NheI_F atattagctagcacgcgtCGAATTCGGGATCAATTCTC
bGHpA_0lox_NheI_R ttattagctaGCCCCAGCTGGTTC
bGHpA_1lox_MluI_NheI_F atattagctagcacgcgTTTAGTAGGGCCAAGTTCAC
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bGHpA_1lox_NheI_R ttattagctagcGTCGATGGTGATGCTTG
bGHpA_flex_MluI_NheI_F atattagctagcacgcgTGCAGGATTATCTAGTCTAGAGCTTATAAC
bGHpA_flex_NheI_R ttattagctaGCCGCGAGCTAGATCTAGAA
mDNAJB6-3_MluI_F aataatacgcgtACAAAAAGGAATGGCCTGG
mDNAJB6-3_SaII_R aataatgtcgacGGTGATAGAAGCAATTCTTTTTATTCTAG
Anti-aggregation
mDNAJB6-3_NheI_F aataatgctagcACAAAAAGGAATGGCCTGG
mDNAJB6-3_SaII_R aataatgtcgacGGTGATAGAAGCAATTCTTTTTATTCTAG
mDNAJB6-2_OuterF TTACAGGATTGTGGAGAACGGT
mDNAJB6-2_OuterR AGCACTAATGAGGTGACACTTAGA
mDNAJB6-2_XbaI_InnerF taataatctagaCTCAACGCACGCATTTAAC
mDNAJB6-2_SalI_InnerR attattgtcgacAGACCCCACTCATGAAAGA
mDNAJB6-1_XbaI_F aataattctagaGCTGGACTTGGCG
mDNAJB6-1_SalI_R aataatgtcgacAAATGTATAAAACTGTATTTAAAAAAAC
mDNAJB6-1-
extended_SalI_R
aataatgtcgacTAGTGTTAGGGTTAAGAGT
mDNAJC6_XbaI_F ttattatctagaTTTGTGAGCTTTTCTATGCTG
mDNAJC6_SalI_R ttctatgtcgacTATTTTGTATCCTTTTTAATATACATTAC
mHSPA1A_XbaI_F tataattctagAGGCCTCTGCTGGCTCTCCCGG
mHSPA1A_SalI_R
aataatgtcgacTGGCAAGTGATTTTGAAGTTTATTTTCAAATGACCG
G
mMITF_OuterF ATGCATTTGGGTAACCGCAC
mMITF_OuterR GTGCCATCTTCGAATGACACAAG
mMITF_NheI_InnerF attattgctagCGAGCCTGCCTTGC
mMITF_SalI_InnerR taataagtcgacAACACAATGTGAAAAACCAAATG
mMME_XbaI_F aataattctagaTCTTCACAAGATACTGAACATCC
mMME_SalI_R ttattagtcgacTTGACACTAAGAAAATATAATTAGAGAAAAAG
mPCSK1N_XbaI_F aataattctagaGCGCTGCTGCATCCTG
mPCSK1N_SalI_R aataatgtcgacTTACCACAGACATCTTTTTATTGTCATTTG
mSCG5_XbaI_F aataattctAGAGAAGACAGTATGTAGAAACC
mSCG5_SalI_R ttattagtcgacATTAAGCAAAGAAATTGATTTTATAC
Aggregation proteins
mAPP_XbaI_F ttattatctagaGCCCCACCCGCGC
mAPP_SalI_R
ttattagtcgacTCTTGCCTGGAGTTATTTTATTTAATTTATTTATGTAAT
ACAG
mAPP_NheI_F ttattagctagcGCCCCACCCGCGC
mAPP-extended_SalI_R ttattagtcgacTCAGGAGGATAAGGCCATCTTTG
mITM2B_XbaI_F ttattatctaGAAGTCAAGAAAAAACGTGG
mITM2B_SalI_R ttattagtcgacTTTAGTAATTAATGGCTTATTTTATTTTTTTAAAAAG
mSNCA_XbaI_F ttattatctaGAATGTCATTGCACCCAATC
mSNCA_SalI_R aataatgtcgacGATTTTGCAATGGATAATATTTTATT
mSNCA-extended_SalI_R ttattagtcgaCTAAACACCATCTGGGCTAC
mIAPP_OuterF CCAACCAACGTGGGATCGAA
mIAPP_OuterR TTTTCAGGCACTGCTCCGT 
mIAPP_NheI_InnerF aattaagctagcAGTCAATGTACTTCTGCAGCACTTAATAC
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mIAPP-extended
_SalI_InnerR
aataatgtcgaCCATTCTTCCGTGACTGAACC
mPRNP_OuterF AGGACCGCTACTACCGTGAA
mPRNP_OuterR GCGCTATCACGTTGTGGTTT
mPRNP_BcuI_InnerF aataatactagtGGGAGGCCTTCCTGCTTG
mPRNP-extended
_SalI_InnerR
aataatgtcgacTGTCTGAGCCAGGTATGGGA
mACTB_OuterF CATCACTATTGGCAACGAGCG
mACTB_OuterR GGTAGCTTATTTAGGGTTGGC
mACTB_XbaI_InnerF aataattctagaGCGGACTGTTACTGAGCTGC
mACTB-extended
_SalI_InnerR
aataatgtcgaCAAAGCTAACTTGCGGCACC 
mSOD1_OuterF GAGCCGTCTTCCCAAGTTACC
mSOD1_OuterR CAGCTTTCTGGTGACCCTACTTA
mSOD1_XbaI_InnerF aataattctagACATTCCCTGTGTGGTCTGAGTC
mSOD1-extended
_SalI_InnerR
aataatgtcgACTTGGTGTCATTCCCCGAG
mTRP53_OuterF CGAGATGTTCCGGGAGCTGA
mTRP53_OuterR TAGTTCTCAGTAAAGCTGTGGGAC
mTRP53_XbaI_InnerF aataattctagaCTCCCATCACTTCATCCCTCC
mTRP53-extended
_SalI_InnerR
aataatgtcgacGAGTTTGGGGATGCTGGGAA
Neuron survival
mGDF11_OuterF CCTGGACTGCGATGAACACT
mGDF11_OuterR AAGGTAGGCCTGAGGGGTAG
mGDF11_XbaI_InnerF taataatctagaGTTGTGGGCTACAGTGGAT
mGDF11_SalI_InnerR attattgtcgacTCCTTACTTTGCCCCATC
mGDNF_NheI_F 
(an attempt to recreate the 
+mGDNF+60bp(+SV40) 
construct)
aattaagctagCCCCGGCTCCAGAGACTG
mGDNF_NheI_R 
(an attempt to recreate the 
+mGDNF+60bp(+SV40) 
construct)
aattaagctaGCCTGCCCGGCCAAGGC
mPARK2-1_XbaI_F aataattctAGAGAGATGTCACTTGGCCCTG
mPARK2-1_SalI_R attgatgtcgacGATTCTTTCATTGACAGTCTGGGTC
9.4. Appendix D:  Raw and processed measurement data
Tables 6 and 7 record the raw and processed luminometer measurements respectively, split into two 
tables to allow for page width.  
Firefly luciferase was expressed by the internal control plasmid pGL4.73 and Renilla luciferase by 
each reporter plasmid derived from plasmid pGL4.73.  The control:reporter plasmid co-transfection 
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ratio is 1:11.8 for days 1-0, 1-1, and 1-2, and 1:10 for all other days except where indicated with a 
different ratio in the 3′UTR designation.  
The 3′UTR designation also indicates number of measurements for each 3′UTR type in the form 
‘_(n=#)’.
The day and 3′UTR type abbreviations are described in Appendix A.
‘Measurement’ refers to the measurement number within each replicate within a given measurement
day.
Table 6. Luminometer unchanged measurements, as described above.
3′UTR Batch Day Measurement Firefly luciferase Renilla luciferase
Viral sequences
(+SV40)_(n=24) 1 1-0 1 5,308,965 95,362,784
(+SV40)_(n=24) 1 1-0 2 5,852,236 105,678,000
(+SV40)_(n=24) 1 1-0 3 5,651,853 102,565,264
(+SV40)_(n=24) 1 1-1 1 2,356,662 44,999,892
(+SV40)_(n=24) 1 1-1 2 3,128,744 80,371,248
(+SV40)_(n=24) 1 1-1 3 1,815,211 47,445,252
(+SV40)_(n=24) 1 1-2 1 1,701,942 50,939,964
(+SV40)_(n=24) 1 1-2 2 3,130,801 119,524,824
(+SV40)_(n=24) 1 1-2 3 2,828,680 99,335,328
(+SV40)_(n=24) 1 1-3 2 926,643 51,865,592
(+SV40)_(n=24) 1 1-3 3 1,008,143 55,199,848
(+SV40)_(n=24) 2 2-1 1 663,556 66,007,720
(+SV40)_(n=24) 2 2-1 2 1,388,227 148,422,688
(+SV40)_(n=24) 2 2-1 3 1,280,164 134,326,704
(+SV40)_(n=24) 2 2-2/3-1 1 3,457,175 176,843,200
(+SV40)_(n=24) 2 2-2/3-1 2 3,163,427 164,197,696
(+SV40)_(n=24) 2 2-2/3-1 3 3,498,232 172,149,728
(+SV40)_(n=24) 3 2-2/3-1 1 8,886,113 555,942,592
(+SV40)_(n=24) 3 2-2/3-1 2 9,437,454 552,014,464
(+SV40)_(n=24) 3 2-2/3-1 3 8,824,526 527,984,768
(+SV40)_(n=24) 3 3-2 1 2,067,841 287,839,296
(+SV40)_(n=24) 3 3-2 2 2,219,196 342,387,616
(+SV40)_(n=24) 3 3-2 3 2,488,922 319,845,696
+WPRE+hGH_(n=6) 3 2-2/3-1 1 3,669,220 963,177,472
+WPRE+hGH_(n=6) 3 2-2/3-1 2 4,150,225 1,074,323,712
+WPRE+hGH_(n=6) 3 2-2/3-1 3 4,580,382 1,121,431,168
+WPRE+hGH_(n=6) 3 3-2 1 1,535,947 621,207,744
+WPRE+hGH_(n=6) 3 3-2 2 1,076,537 497,969,920
+WPRE+hGH_(n=6) 3 3-2 3 1,352,831 580,466,560
Flex-cassette testing
+0lox-F(+SV40)_(n=12) 2 2-1 1 965,991 36,619,148
+0lox-F(+SV40)_(n=12) 2 2-1 2 1,158,535 42,851,960
+0lox-F(+SV40)_(n=12) 2 2-1 3 1,153,313 46,132,972
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 1 4,030,095 98,602,368
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 2 3,820,136 92,704,928
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 3 3,621,798 83,684,016
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+0lox-F(+SV40)_(n=12) 3 2-2/3-1 1 7,524,540 159,939,328
+0lox-F(+SV40)_(n=12) 3 2-2/3-1 2 8,557,831 176,001,296
+0lox-F(+SV40)_(n=12) 3 3-2 1 1,983,213 96,376,640
+0lox-F(+SV40)_(n=12) 3 3-2 2 2,827,349 133,969,264
+0lox-F(+SV40)_(n=12) 3 3-2 3 2,995,375 134,752,144
+1lox-F(+SV40)_(n=6) 2 2-1 1 1,032,376 30,432,402
+1lox-F(+SV40)_(n=6) 2 2-1 2 1,175,686 30,363,526
+1lox-F(+SV40)_(n=6) 2 2-1 3 1,326,094 34,693,364
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 1 4,601,312 79,110,384
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 2 4,433,532 75,665,328
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 3 3,936,512 68,866,784
+flex-F(+SV40)_(n=18) 1 1-0 1 237,688 5,007,632
+flex-F(+SV40)_(n=18) 1 1-0 2 232,388 5,619,819
+flex-F(+SV40)_(n=18) 1 1-0 3 257,786 5,265,715
+flex-F(+SV40)_(n=18) 1 1-1 1 4,553,205 19,705,838
+flex-F(+SV40)_(n=18) 1 1-1 2 6,107,946 28,253,350
+flex-F(+SV40)_(n=18) 1 1-1 3 6,381,508 27,081,802
+flex-F(+SV40)_(n=18) 1 1-2 1 7,584,637 57,428,700
+flex-F(+SV40)_(n=18) 1 1-2 2 5,536,485 45,111,844
+flex-F(+SV40)_(n=18) 1 1-2 3 7,073,510 54,040,556
+flex-F(+SV40)_(n=18) 1 1-3 1 877,871 14,794,245
+flex-F(+SV40)_(n=18) 1 1-3 2 1,079,873 16,717,230
+flex-F(+SV40)_(n=18) 1 1-3 3 1,039,361 16,988,414
+flex-F(+SV40)_(n=18) 2 2-1 1 840,512 19,415,054
+flex-F(+SV40)_(n=18) 2 2-1 2 1,025,992 22,913,550
+flex-F(+SV40)_(n=18) 2 2-1 3 916,677 16,720,136
+flex-F(+SV40)_(n=18) 2 2-2/3-1 1 3,493,269 46,324,892
+flex-F(+SV40)_(n=18) 2 2-2/3-1 2 4,015,976 55,527,936
+flex-F(+SV40)_(n=18) 2 2-2/3-1 3 3,519,718 50,399,928
+flex-F
(no_SV40)_(n=6)
2 2-1 1 613,516 12,881,890
+flex-F
(no_SV40)_(n=6)
2 2-1 2 729,500 14,505,879
+flex-F
(no_SV40)_(n=6)
2 2-1 3 867,171 17,641,156
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 1 2,365,682 28,609,076
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 2 2,526,322 28,057,574
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 3 2,119,628 24,088,124
+0lox-B(+SV40)_(n=6) 2 2-1 1 771,139 66,746,668
+0lox-B(+SV40)_(n=6) 2 2-1 2 993,762 78,604,496
+0lox-B(+SV40)_(n=6) 2 2-1 3 1,130,521 96,417,240
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 1 3,430,323 179,917,040
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 2 3,541,597 191,829,168
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 3 3,337,722 169,485,168
+1lox-B(+SV40)_(n=6) 2 2-1 1 1,070,179 32,391,502
+1lox-B(+SV40)_(n=6) 2 2-1 2 852,118 24,513,854
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+1lox-B(+SV40)_(n=6) 2 2-1 3 1,022,381 27,928,394
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 1 7,073,542 126,191,720
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 2 7,087,911 134,069,712
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 3 6,391,504 127,111,416
+flex-B(+SV40)_(n=18) 1 1-0 1 4,919,098 10,511,795
+flex-B(+SV40)_(n=18) 1 1-0 2 4,964,934 9,748,039
+flex-B(+SV40)_(n=18) 1 1-0 3 4,673,697 9,980,481
+flex-B(+SV40)_(n=18) 1 1-1 1 4,036,619 11,264,284
+flex-B(+SV40)_(n=18) 1 1-1 2 4,801,505 12,712,927
+flex-B(+SV40)_(n=18) 1 1-1 3 3,274,777 5,770,324
+flex-B(+SV40)_(n=18) 1 1-2 1 7,353,360 35,624,556
+flex-B(+SV40)_(n=18) 1 1-2 2 5,212,015 28,162,058
+flex-B(+SV40)_(n=18) 1 1-2 3 7,267,230 39,599,704
+flex-B(+SV40)_(n=18) 1 1-3 1 837,932 5,004,004
+flex-B(+SV40)_(n=18) 1 1-3 2 885,538 5,316,198
+flex-B(+SV40)_(n=18) 1 1-3 3 771,007 5,489,492
+flex-B(+SV40)_(n=18) 2 2-1 1 441,389 5,430,486
+flex-B(+SV40)_(n=18) 2 2-1 2 1,019,031 13,526,798
+flex-B(+SV40)_(n=18) 2 2-1 3 955,828 12,355,942
+flex-B(+SV40)_(n=18) 2 2-2/3-1 1 3,889,764 36,137,300
+flex-B(+SV40)_(n=18) 2 2-2/3-1 2 4,436,120 41,024,220
+flex-B(+SV40)_(n=18) 2 2-2/3-1 3 4,056,054 34,060,836
+flex-B
(no_SV40)_(n=6)
2 2-1 1 880,624 1,439,577
+flex-B
(no_SV40)_(n=6)
2 2-1 2 950,408 1,522,968
+flex-B
(no_SV40)_(n=6)
2 2-1 3 930,524 1,491,788
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 1 2,065,421 1,608,606
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 2 2,272,481 1,621,328
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 3 1,718,645 1,363,163
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 1 6,167,922 1,618,802
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 2 5,626,580 1,380,764
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 3 5,593,556 1,302,744
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 1 776,037 700,177
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 2 874,875 857,030
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 3 801,664 662,533
+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 1 3,346,106 2,283,794
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+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 2 7,232,244 4,814,509
+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 3 7,891,228 5,118,635
Anti-aggregation
+mDNAJB6-3_(n=15) 1 1-1 1 2,184,594 23,967,620
+mDNAJB6-3_(n=15) 1 1-1 2 2,485,570 28,804,618
+mDNAJB6-3_(n=15) 1 1-1 3 2,894,751 34,286,884
+mDNAJB6-3_(n=15) 1 1-2 1 1,394,323 15,262,985
+mDNAJB6-3_(n=15) 1 1-2 2 2,198,623 26,113,408
+mDNAJB6-3_(n=15) 1 1-2 3 1,863,264 23,501,858
+mDNAJB6-3_(n=15) 1 1-3 1 425,710 3,218,790
+mDNAJB6-3_(n=15) 1 1-3 2 535,466 4,040,734
+mDNAJB6-3_(n=15) 1 1-3 3 683,633 5,178,380
+mDNAJB6-3_(n=15) 2 2-1 1 462,698 5,647,587
+mDNAJB6-3_(n=15) 2 2-1 2 689,911 9,351,981
+mDNAJB6-3_(n=15) 2 2-1 3 642,140 8,676,932
+mDNAJB6-3_(n=15) 2 2-2/3-1 1 1,928,097 14,048,780
+mDNAJB6-3_(n=15) 2 2-2/3-1 2 2,170,199 15,575,222
+mDNAJB6-3_(n=15) 2 2-2/3-1 3 1,588,989 11,967,514
+mDNAJB6-2_(n=6) 2 2-1 1 1,049,891 157,114,432
+mDNAJB6-2_(n=6) 2 2-1 2 1,146,044 180,627,872
+mDNAJB6-2_(n=6) 2 2-1 3 990,731 163,446,288
+mDNAJB6-2_(n=6) 2 2-2/3-1 1 1,551,631 114,651,864
+mDNAJB6-2_(n=6) 2 2-2/3-1 2 1,760,207 137,206,688
+mDNAJB6-2_(n=6) 2 2-2/3-1 3 1,519,321 122,818,040
+mDNAJB6-1_(n=21) 1 1-1 1 3,158,073 3,078,380
+mDNAJB6-1_(n=21) 1 1-1 2 4,431,315 4,354,015
+mDNAJB6-1_(n=21) 1 1-1 3 3,651,141 3,786,360
+mDNAJB6-1_(n=21) 1 1-2 1 4,897,150 5,163,375
+mDNAJB6-1_(n=21) 1 1-2 2 3,471,893 3,463,889
+mDNAJB6-1_(n=21) 1 1-2 3 4,722,548 5,377,855
+mDNAJB6-1_(n=21) 1 1-3 1 739,151 2,087,518
+mDNAJB6-1_(n=21) 1 1-3 2 914,426 2,208,191
+mDNAJB6-1_(n=21) 1 1-3 3 978,536 2,407,067
+mDNAJB6-1_(n=21) 2 2-1 1 649,771 2,153,218
+mDNAJB6-1_(n=21) 2 2-1 2 901,675 3,034,103
+mDNAJB6-1_(n=21) 2 2-1 3 1,101,410 3,811,986
+mDNAJB6-1_(n=21) 2 2-2/3-1 1 4,538,213 11,608,278
+mDNAJB6-1_(n=21) 2 2-2/3-1 2 4,957,758 12,209,776
+mDNAJB6-1_(n=21) 2 2-2/3-1 3 4,761,719 11,257,890
+mDNAJB6-1_(n=21) 3 2-2/3-1 1 8,228,159 21,523,228
+mDNAJB6-1_(n=21) 3 2-2/3-1 2 10,729,239 27,801,124
+mDNAJB6-1_(n=21) 3 2-2/3-1 3 8,798,327 22,804,666
+mDNAJB6-1_(n=21) 3 3-2 1 1,730,446 13,076,750
+mDNAJB6-1_(n=21) 3 3-2 2 2,734,932 18,451,030
+mDNAJB6-1_(n=21) 3 3-2 3 3,129,602 20,501,502
+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 1 9,773,793 19,756,516
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+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 2 9,754,878 18,297,524
+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 3 11,199,219 19,425,974
+mDNAJB6-1-
extended_(n=6)
3 3-2 1 3,617,104 17,996,350
+mDNAJB6-1-
extended_(n=6)
3 3-2 2 3,189,414 16,357,744
+mDNAJB6-1-
extended_(n=6)
3 3-2 3 3,299,528 15,360,104
+mDNAJC6_(n=9) 1 1-1 1 1,931,648 158,827,584
+mDNAJC6_(n=9) 1 1-1 2 1,396,543 112,342,888
+mDNAJC6_(n=9) 1 1-1 3 1,309,534 99,322,608
+mDNAJC6_(n=9) 1 1-2 1 1,370,722 113,855,592
+mDNAJC6_(n=9) 1 1-2 2 1,580,304 149,204,896
+mDNAJC6_(n=9) 1 1-2 3 1,549,482 97,951,640
+mDNAJC6_(n=9) 1 1-3 1 583,241 54,431,056
+mDNAJC6_(n=9) 1 1-3 2 744,495 48,563,652
+mDNAJC6_(n=9) 1 1-3 3 626,587 54,272,068
+mHSPA1A_(n=12) 1 1-0 1 5,141,962 54,533,684
+mHSPA1A_(n=12) 1 1-0 2 5,302,622 61,757,752
+mHSPA1A_(n=12) 1 1-0 3 4,336,639 49,957,260
+mHSPA1A_(n=12) 1 1-1 1 1,440,472 23,083,028
+mHSPA1A_(n=12) 1 1-1 2 2,496,694 46,640,072
+mHSPA1A_(n=12) 1 1-1 3 2,836,981 57,286,184
+mHSPA1A_(n=12) 1 1-2 1 3,388,763 93,405,176
+mHSPA1A_(n=12) 1 1-2 2 3,418,954 97,135,920
+mHSPA1A_(n=12) 1 1-2 3 2,860,218 79,377,208
+mHSPA1A_(n=12) 1 1-3 1 709,958 20,122,718
+mHSPA1A_(n=12) 1 1-3 2 910,646 22,891,532
+mHSPA1A_(n=12) 1 1-3 3 882,158 24,398,922
+mMITF_(n=6) 2 2-1 1 791,040 26,788,976
+mMITF_(n=6) 2 2-1 2 923,111 36,661,504
+mMITF_(n=6) 2 2-1 3 1,007,568 42,032,740
+mMITF_(n=6) 2 2-2/3-1 1 6,209,355 190,394,480
+mMITF_(n=6) 2 2-2/3-1 2 5,899,692 190,770,384
+mMITF_(n=6) 2 2-2/3-1 3 5,867,711 184,840,304
+mMME_(n=9) 1 1-1 1 3,007,419 12,700,351
+mMME_(n=9) 1 1-1 2 3,134,802 14,563,416
+mMME_(n=9) 1 1-1 3 4,235,676 18,142,974
+mMME_(n=9) 1 1-2 1 2,061,369 12,877,383
+mMME_(n=9) 1 1-2 2 1,073,664 5,433,800
+mMME_(n=9) 1 1-2 3 1,291,699 7,724,833
+mMME_(n=9) 1 1-3 1 594,174 2,585,383
+mMME_(n=9) 1 1-3 2 664,931 2,965,592
+mMME_(n=9) 1 1-3 3 787,140 3,470,179
+mPCSK1N_(n=9) 1 1-1 1 3,140,344 56,651,664
+mPCSK1N_(n=9) 1 1-1 2 3,677,602 76,443,296
+mPCSK1N_(n=9) 1 1-2 1 4,035,710 126,664,632
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+mPCSK1N_(n=9) 1 1-2 2 3,282,274 102,504,520
+mPCSK1N_(n=9) 1 1-2 3 4,047,297 127,926,408
+mPCSK1N_(n=9) 1 1-3 1 770,921 19,754,864
+mPCSK1N_(n=9) 1 1-3 2 1,174,415 31,148,554
+mPCSK1N_(n=9) 1 1-3 3 1,353,450 33,580,592
+mSCG5_(n=9) 1 1-1 1 2,995,877 30,688,960
+mSCG5_(n=9) 1 1-1 2 3,306,599 36,834,836
+mSCG5_(n=9) 1 1-1 3 2,591,768 26,755,616
+mSCG5_(n=9) 1 1-2 1 2,813,309 61,806,740
+mSCG5_(n=9) 1 1-2 2 3,824,876 74,305,968
+mSCG5_(n=9) 1 1-2 3 3,086,331 62,317,556
+mSCG5_(n=9) 1 1-3 1 757,158 21,024,166
+mSCG5_(n=9) 1 1-3 2 806,551 23,065,666
+mSCG5_(n=9) 1 1-3 3 716,949 20,741,116
Aggregation proteins
+mAPP_(n=18) 1 1-0 1 3,764,489 193,570,528
+mAPP_(n=18) 1 1-0 2 3,451,815 188,737,152
+mAPP_(n=18) 1 1-0 3 3,538,620 179,744,464
+mAPP_(n=18) 1 1-1 1 2,709,339 169,222,704
+mAPP_(n=18) 1 1-1 2 2,423,342 169,018,752
+mAPP_(n=18) 1 1-1 3 3,476,245 227,390,240
+mAPP_(n=18) 1 1-2 1 3,036,727 326,105,824
+mAPP_(n=18) 1 1-2 2 4,198,443 486,385,888
+mAPP_(n=18) 1 1-2 3 3,638,537 436,705,728
+mAPP_(n=18) 1 1-3 1 433,188 38,325,884
+mAPP_(n=18) 1 1-3 2 625,248 56,626,980
+mAPP_(n=18) 1 1-3 3 570,287 49,791,812
+mAPP_(n=18) 3 2-2/3-1 1 6,445,421 521,362,240
+mAPP_(n=18) 3 2-2/3-1 2 6,380,531 516,765,120
+mAPP_(n=18) 3 3-2 1 1,926,196 321,567,040
+mAPP_(n=18) 3 3-2 2 1,792,884 347,593,024
+mAPP_(n=18) 3 3-2 3 2,215,148 343,203,712
+mAPP-extended_(n=6) 3 2-2/3-1 1 7,405,352 581,122,752
+mAPP-extended_(n=6) 3 2-2/3-1 2 7,837,914 614,488,896
+mAPP-extended_(n=6) 3 2-2/3-1 3 8,975,949 748,125,440
+mAPP-extended_(n=6) 3 3-2 1 2,119,866 362,173,216
+mAPP-extended_(n=6) 3 3-2 2 1,865,424 285,733,280
+mAPP-extended_(n=6) 3 3-2 3 2,511,367 390,114,624
+mITM2B_(n=12) 1 1-0 1 3,298,844 37,082,548
+mITM2B_(n=12) 1 1-0 2 4,256,839 46,073,044
+mITM2B_(n=12) 1 1-0 3 4,327,003 43,910,656
+mITM2B_(n=12) 1 1-1 1 2,635,957 36,343,844
+mITM2B_(n=12) 1 1-1 2 3,552,630 58,466,496
+mITM2B_(n=12) 1 1-1 3 1,914,405 36,919,696
+mITM2B_(n=12) 1 1-2 1 5,155,957 85,657,896
+mITM2B_(n=12) 1 1-2 2 8,666,783 131,203,864
+mITM2B_(n=12) 1 1-2 3 5,178,267 85,585,912
+mITM2B_(n=12) 1 1-3 1 445,018 9,593,262
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+mITM2B_(n=12) 1 1-3 2 531,967 13,307,362
+mITM2B_(n=12) 1 1-3 3 689,067 15,538,999
+mSNCA_(n=15) 1 1-1 1 2,198,095 69,516,192
+mSNCA_(n=15) 1 1-1 2 2,409,681 99,285,032
+mSNCA_(n=15) 1 1-1 3 3,081,830 129,965,384
+mSNCA_(n=15) 1 1-2 1 4,013,221 222,530,432
+mSNCA_(n=15) 1 1-2 2 4,386,535 241,048,320
+mSNCA_(n=15) 1 1-2 3 3,697,762 201,459,888
+mSNCA_(n=15) 1 1-3 1 790,871 39,950,396
+mSNCA_(n=15) 1 1-3 2 716,877 37,297,904
+mSNCA_(n=15) 1 1-3 3 579,917 38,592,984
+mSNCA_(n=15) 3 2-2/3-1 1 4,296,286 226,028,352
+mSNCA_(n=15) 3 2-2/3-1 2 5,745,563 311,128,768
+mSNCA_(n=15) 3 2-2/3-1 3 4,926,860 260,769,088
+mSNCA_(n=15) 3 3-2 1 42,866 3,059,793
+mSNCA_(n=15) 3 3-2 2 186,036 15,524,640
+mSNCA_(n=15) 3 3-2 3 157,891 12,006,691
+mSNCA-
extended_(n=6)
3 2-2/3-1 1 4,752,943 175,525,696
+mSNCA-
extended_(n=6)
3 2-2/3-1 2 4,770,641 176,043,024
+mSNCA-
extended_(n=6)
3 2-2/3-1 3 4,396,205 161,576,736
+mSNCA-
extended_(n=6)
3 3-2 1 1,850,154 119,695,352
+mSNCA-
extended_(n=6)
3 3-2 2 2,078,214 149,039,184
+mSNCA-
extended_(n=6)
3 3-2 3 1,814,852 117,684,968
+mIAPP-
extended_(n=6)
3 2-2/3-1 1 7,055,182 200,397,232
+mIAPP-
extended_(n=6)
3 2-2/3-1 2 7,886,051 216,894,272
+mIAPP-
extended_(n=6)
3 2-2/3-1 3 8,202,903 243,098,128
+mIAPP-
extended_(n=6)
3 3-2 2 2,067,639 122,373,624
+mIAPP-
extended_(n=6)
3 3-2 3 1,982,986 107,966,032
+mPRNP-
extended_(n=6)
3 2-2/3-1 2 10,432,471 68,387,624
+mPRNP-
extended_(n=6)
3 2-2/3-1 3 11,316,850 75,078,040
+mPRNP-
extended_(n=6)
3 3-2 1 3,508,529 45,712,464
+mPRNP-
extended_(n=6)
3 3-2 2 3,510,653 45,031,552
+mPRNP-
extended_(n=6)
3 3-2 3 3,137,964 44,469,736
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+mACTB-
extended_(n=6)
3 2-2/3-1 2 10,003,239 896,003,072
+mACTB-
extended_(n=6)
3 2-2/3-1 3 10,406,100 992,234,560
+mACTB-
extended_(n=6)
3 3-2 1 3,122,085 540,008,960
+mACTB-
extended_(n=6)
3 3-2 2 2,944,685 499,472,224
+mACTB-
extended_(n=6)
3 3-2 3 2,694,632 471,478,784
+mSOD1-
extended_(n=6)
3 2-2/3-1 1 9,958,320 129,519,184
+mSOD1-
extended_(n=6)
3 2-2/3-1 2 9,455,389 128,769,544
+mSOD1-
extended_(n=6)
3 2-2/3-1 3 9,634,607 125,221,240
+mSOD1-
extended_(n=6)
3 3-2 1 2,943,328 88,220,248
+mSOD1-
extended_(n=6)
3 3-2 2 2,882,976 81,957,096
+mSOD1-
extended_(n=6)
3 3-2 3 2,612,252 76,062,232
+mTRP53-
extended_(n=6)
3 2-2/3-1 1 5,664,725 55,817,852
+mTRP53-
extended_(n=6)
3 2-2/3-1 2 7,507,474 71,197,424
+mTRP53-
extended_(n=6)
3 2-2/3-1 3 6,270,685 61,929,404
+mTRP53-
extended_(n=6)
3 3-2 1 2,238,850 40,003,596
+mTRP53-
extended_(n=6)
3 3-2 2 1,868,744 36,313,404
+mTRP53-
extended_(n=6)
3 3-2 3 1,641,661 26,337,938
Neuron survival
+mGDF11_(n=6) 2 2-1 1 824,876 138,116
+mGDF11_(n=6) 2 2-1 2 1,060,304 167,050
+mGDF11_(n=6) 2 2-1 3 1,150,555 157,637
+mGDF11_(n=6) 2 2-2/3-1 1 2,617,892 233,651
+mGDF11_(n=6) 2 2-2/3-1 2 3,108,612 240,967
+mGDF11_(n=6) 2 2-2/3-1 3 2,572,953 198,165
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 1 5,603,662 23,286,982
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 2 4,184,035 17,924,162
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 3 3,856,008 17,288,910
+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 1 4,440,121 15,561,043
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+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 2 3,523,944 13,534,470
+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 3 3,400,972 13,790,621
+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 1 3,877,787 20,252,880
+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 2 2,673,036 10,192,005
+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 3 2,826,001 12,999,661
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 1 853,883 7,146,307
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 2 947,655 5,612,355
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 3 1,188,121 9,335,436
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 1 612,495 5,454,804
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 2 757,718 5,783,183
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 3 863,246 7,790,051
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 1 5,028,986 31,286,586
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 2 5,284,666 31,729,904
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 3 5,067,256 29,722,294
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 1 647,219 4,508,758
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 2 1,046,806 5,580,139
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 3 1,084,279 5,640,239
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 1 7,411,704 30,738,986
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 2 6,393,391 25,575,520
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 3 6,137,552 25,982,916
+mPARK2-1_(n=9) 1 1-1 1 3,543,028 16,935,514
+mPARK2-1_(n=9) 1 1-1 2 3,333,414 17,952,554
+mPARK2-1_(n=9) 1 1-1 3 3,351,118 17,610,430
+mPARK2-1_(n=9) 1 1-2 1 3,136,001 18,941,298
+mPARK2-1_(n=9) 1 1-2 2 2,802,088 17,068,896
+mPARK2-1_(n=9) 1 1-2 3 3,059,956 20,676,398
+mPARK2-1_(n=9) 1 1-3 1 927,440 5,129,966
+mPARK2-1_(n=9) 1 1-3 2 902,328 4,799,656
+mPARK2-1_(n=9) 1 1-3 3 952,239 5,077,141
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Co-transfection ratio testing
(+SV40)-1:10_(n=3) 3 3-2 1 1,645,404 287,570,208
(+SV40)-1:10_(n=3) 3 3-2 2 1,930,140 371,473,824
(+SV40)-1:10_(n=3) 3 3-2 3 1,974,338 361,010,368
(+SV40)-1:25_(n=3) 3 3-2 1 530,215 207,639,472
(+SV40)-1:25_(n=3) 3 3-2 2 712,376 274,280,640
(+SV40)-1:25_(n=3) 3 3-2 3 870,615 346,753,056
+mAPP-1:10_(n=3) 3 3-2 1 2,273,780 407,255,712
+mAPP-1:10_(n=3) 3 3-2 2 2,684,856 488,776,960
+mAPP-1:10_(n=3) 3 3-2 3 2,703,615 496,153,856
+mAPP-1:25_(n=3) 3 3-2 1 805,977 404,170,272
+mAPP-1:25_(n=3) 3 3-2 2 886,807 532,754,624
+mAPP-1:25_(n=3) 3 3-2 3 1,225,314 627,739,200
(+SV40)-1:10_(n=3) 4 4-0 1 1,386,951 288,300,800
(+SV40)-1:10_(n=3) 4 4-0 2 1,540,991 309,665,472
(+SV40)-1:10_(n=3) 4 4-0 3 1,370,880 272,871,584
+mAPP-1:10_(n=3) 4 4-0 1 423,263 87,011,336
+mAPP-1:10_(n=3) 4 4-0 2 372,327 71,338,968
+mAPP-1:10_(n=3) 4 4-0 3 372,449 70,860,264
(+SV40)-1:20_(n=3) 4 4-0 1 778,535 302,028,096
(+SV40)-1:20_(n=3) 4 4-0 2 673,021 289,435,040
(+SV40)-1:20_(n=3) 4 4-0 3 792,652 322,403,232
+mAPP-1:20_(n=3) 4 4-0 1 254,617 101,555,672
+mAPP-1:20_(n=3) 4 4-0 2 247,934 110,987,800
+mAPP-1:20_(n=3) 4 4-0 3 182,580 70,870,440
(+SV40)-1:40_(n=3) 4 4-0 1 299,200 245,055,648
(+SV40)-1:40_(n=3) 4 4-0 2 292,438 226,919,584
(+SV40)-1:40_(n=3) 4 4-0 3 333,379 247,150,544
+mAPP-1:40_(n=3) 4 4-0 1 103,458 84,155,504
+mAPP-1:40_(n=3) 4 4-0 2 104,358 85,078,416
+mAPP-1:40_(n=3) 4 4-0 3 93,571 70,775,232
(+SV40)-1:80_(n=3) 4 4-0 1 176,014 294,641,728
(+SV40)-1:80_(n=3) 4 4-0 2 131,747 219,011,664
(+SV40)-1:80_(n=3) 4 4-0 3 168,178 263,804,832
+mAPP-1:80_(n=3) 4 4-0 1 58,271 94,549,552
+mAPP-1:80_(n=3) 4 4-0 2 52,746 96,008,240
+mAPP-1:80_(n=3) 4 4-0 3 60,100 103,506,440
(+SV40)-1:160_(n=3) 4 4-0 1 108,718 383,419,840
(+SV40)-1:160_(n=3) 4 4-0 2 91,695 322,608,352
(+SV40)-1:160_(n=3) 4 4-0 3 89,471 302,562,720
+mAPP-1:160_(n=3) 4 4-0 1 31,871 109,909,992
+mAPP-1:160_(n=3) 4 4-0 2 28,428 88,463,200
+mAPP-1:160_(n=3) 4 4-0 3 28,100 91,902,000
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Table 7. (Renilla/Firefly) luminometer unadjusted and day-adjusted measurement ratios calculated from Table 6's raw 
measurement data, rounded to two decimal places.
3′UTR Batch Day Measurement
(Renilla/
Firefly)
Log2(Renilla
/Firefly)
Day-adjusted
Log2(Renilla/
Firefly)
Viral sequences
(+SV40)_(n=24) 1 1-0 1 17.96 4.17 -0.90
(+SV40)_(n=24) 1 1-0 2 18.06 4.17 -0.90
(+SV40)_(n=24) 1 1-0 3 18.15 4.18 -0.89
(+SV40)_(n=24) 1 1-1 1 19.09 4.26 -0.73
(+SV40)_(n=24) 1 1-1 2 25.69 4.68 -0.30
(+SV40)_(n=24) 1 1-1 3 26.14 4.71 -0.28
(+SV40)_(n=24) 1 1-2 1 29.93 4.90 -0.80
(+SV40)_(n=24) 1 1-2 2 38.18 5.25 -0.45
(+SV40)_(n=24) 1 1-2 3 35.12 5.13 -0.57
(+SV40)_(n=24) 1 1-3 2 55.97 5.81 0.07
(+SV40)_(n=24) 1 1-3 3 54.75 5.77 0.04
(+SV40)_(n=24) 2 2-1 1 99.48 6.64 0.14
(+SV40)_(n=24) 2 2-1 2 106.92 6.74 0.25
(+SV40)_(n=24) 2 2-1 3 104.93 6.71 0.22
(+SV40)_(n=24) 2 2-2/3-1 1 51.15 5.68 -0.07
(+SV40)_(n=24) 2 2-2/3-1 2 51.91 5.70 -0.05
(+SV40)_(n=24) 2 2-2/3-1 3 49.21 5.62 -0.12
(+SV40)_(n=24) 3 2-2/3-1 1 62.56 5.97 0.22
(+SV40)_(n=24) 3 2-2/3-1 2 58.49 5.87 0.13
(+SV40)_(n=24) 3 2-2/3-1 3 59.83 5.90 0.16
(+SV40)_(n=24) 3 3-2 1 139.20 7.12 0.36
(+SV40)_(n=24) 3 3-2 2 154.28 7.27 0.51
(+SV40)_(n=24) 3 3-2 3 128.51 7.01 0.25
+WPRE+hGH_(n=6) 3 2-2/3-1 1 262.50 8.04 2.29
+WPRE+hGH_(n=6) 3 2-2/3-1 2 258.86 8.02 2.27
+WPRE+hGH_(n=6) 3 2-2/3-1 3 244.83 7.94 2.19
+WPRE+hGH_(n=6) 3 3-2 1 404.45 8.66 1.90
+WPRE+hGH_(n=6) 3 3-2 2 462.57 8.85 2.09
+WPRE+hGH_(n=6) 3 3-2 3 429.08 8.75 1.98
Flex-cassette testing
+0lox-F(+SV40)_(n=12) 2 2-1 1 37.91 5.24 -1.25
+0lox-F(+SV40)_(n=12) 2 2-1 2 36.99 5.21 -1.29
+0lox-F(+SV40)_(n=12) 2 2-1 3 40.00 5.32 -1.17
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 1 24.47 4.61 -1.13
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 2 24.27 4.60 -1.14
+0lox-F(+SV40)_(n=12) 2 2-2/3-1 3 23.11 4.53 -1.21
+0lox-F(+SV40)_(n=12) 3 2-2/3-1 1 21.26 4.41 -1.33
+0lox-F(+SV40)_(n=12) 3 2-2/3-1 2 20.57 4.36 -1.38
+0lox-F(+SV40)_(n=12) 3 3-2 1 48.60 5.60 -1.16
+0lox-F(+SV40)_(n=12) 3 3-2 2 47.38 5.57 -1.19
+0lox-F(+SV40)_(n=12) 3 3-2 3 44.99 5.49 -1.27
+1lox-F(+SV40)_(n=6) 2 2-1 1 29.48 4.88 -1.61
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+1lox-F(+SV40)_(n=6) 2 2-1 2 25.83 4.69 -1.80
+1lox-F(+SV40)_(n=6) 2 2-1 3 26.16 4.71 -1.79
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 1 17.19 4.10 -1.64
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 2 17.07 4.09 -1.65
+1lox-F(+SV40)_(n=6) 2 2-2/3-1 3 17.49 4.13 -1.61
+flex-F(+SV40)_(n=18) 1 1-0 1 21.07 4.40 -0.67
+flex-F(+SV40)_(n=18) 1 1-0 2 24.18 4.60 -0.47
+flex-F(+SV40)_(n=18) 1 1-0 3 20.43 4.35 -0.72
+flex-F(+SV40)_(n=18) 1 1-1 1 4.33 2.11 -2.87
+flex-F(+SV40)_(n=18) 1 1-1 2 4.63 2.21 -2.77
+flex-F(+SV40)_(n=18) 1 1-1 3 4.24 2.09 -2.90
+flex-F(+SV40)_(n=18) 1 1-2 1 7.57 2.92 -2.79
+flex-F(+SV40)_(n=18) 1 1-2 2 8.15 3.03 -2.68
+flex-F(+SV40)_(n=18) 1 1-2 3 7.64 2.93 -2.77
+flex-F(+SV40)_(n=18) 1 1-3 1 16.85 4.07 -1.66
+flex-F(+SV40)_(n=18) 1 1-3 2 15.48 3.95 -1.78
+flex-F(+SV40)_(n=18) 1 1-3 3 16.35 4.03 -1.71
+flex-F(+SV40)_(n=18) 2 2-1 1 23.10 4.53 -1.96
+flex-F(+SV40)_(n=18) 2 2-1 2 22.33 4.48 -2.01
+flex-F(+SV40)_(n=18) 2 2-1 3 18.24 4.19 -2.31
+flex-F(+SV40)_(n=18) 2 2-2/3-1 1 13.26 3.73 -2.01
+flex-F(+SV40)_(n=18) 2 2-2/3-1 2 13.83 3.79 -1.95
+flex-F(+SV40)_(n=18) 2 2-2/3-1 3 14.32 3.84 -1.90
+flex-F
(no_SV40)_(n=6)
2 2-1 1 21.00 4.39 -2.10
+flex-F
(no_SV40)_(n=6)
2 2-1 2 19.88 4.31 -2.18
+flex-F
(no_SV40)_(n=6)
2 2-1 3 20.34 4.35 -2.15
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 1 12.09 3.60 -2.15
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 2 11.11 3.47 -2.27
+flex-F
(no_SV40)_(n=6)
2 2-2/3-1 3 11.36 3.51 -2.24
+0lox-B(+SV40)_(n=6) 2 2-1 1 86.56 6.44 -0.06
+0lox-B(+SV40)_(n=6) 2 2-1 2 79.10 6.31 -0.19
+0lox-B(+SV40)_(n=6) 2 2-1 3 85.29 6.41 -0.08
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 1 52.45 5.71 -0.03
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 2 54.16 5.76 0.02
+0lox-B(+SV40)_(n=6) 2 2-2/3-1 3 50.78 5.67 -0.08
+1lox-B(+SV40)_(n=6) 2 2-1 1 30.27 4.92 -1.57
+1lox-B(+SV40)_(n=6) 2 2-1 2 28.77 4.85 -1.65
+1lox-B(+SV40)_(n=6) 2 2-1 3 27.32 4.77 -1.72
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 1 17.84 4.16 -1.59
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 2 18.92 4.24 -1.50
+1lox-B(+SV40)_(n=6) 2 2-2/3-1 3 19.89 4.31 -1.43
+flex-B(+SV40)_(n=18) 1 1-0 1 2.14 1.10 -3.98
+flex-B(+SV40)_(n=18) 1 1-0 2 1.96 0.97 -4.10
Page 67 of 75
+flex-B(+SV40)_(n=18) 1 1-0 3 2.14 1.09 -3.98
+flex-B(+SV40)_(n=18) 1 1-1 1 2.79 1.48 -3.50
+flex-B(+SV40)_(n=18) 1 1-1 2 2.65 1.40 -3.58
+flex-B(+SV40)_(n=18) 1 1-1 3 1.76 0.82 -4.17
+flex-B(+SV40)_(n=18) 1 1-2 1 4.84 2.28 -3.43
+flex-B(+SV40)_(n=18) 1 1-2 2 5.40 2.43 -3.27
+flex-B(+SV40)_(n=18) 1 1-2 3 5.45 2.45 -3.26
+flex-B(+SV40)_(n=18) 1 1-3 1 5.97 2.58 -3.16
+flex-B(+SV40)_(n=18) 1 1-3 2 6.00 2.59 -3.15
+flex-B(+SV40)_(n=18) 1 1-3 3 7.12 2.83 -2.90
+flex-B(+SV40)_(n=18) 2 2-1 1 12.30 3.62 -2.87
+flex-B(+SV40)_(n=18) 2 2-1 2 13.27 3.73 -2.76
+flex-B(+SV40)_(n=18) 2 2-1 3 12.93 3.69 -2.80
+flex-B(+SV40)_(n=18) 2 2-2/3-1 1 9.29 3.22 -2.53
+flex-B(+SV40)_(n=18) 2 2-2/3-1 2 9.25 3.21 -2.53
+flex-B(+SV40)_(n=18) 2 2-2/3-1 3 8.40 3.07 -2.67
+flex-B
(no_SV40)_(n=6)
2 2-1 1 1.63 0.71 -5.79
+flex-B
(no_SV40)_(n=6)
2 2-1 2 1.60 0.68 -5.81
+flex-B
(no_SV40)_(n=6)
2 2-1 3 1.60 0.68 -5.81
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 1 0.78 -0.36 -6.10
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 2 0.71 -0.49 -6.23
+flex-B
(no_SV40)_(n=6)
2 2-2/3-1 3 0.79 -0.33 -6.08
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 1 0.26 -1.93 -7.64
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 2 0.25 -2.03 -7.73
+flex-B+mDNAJB6-
3_(n=9)
1 1-2 3 0.23 -2.10 -7.81
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 1 0.90 -0.15 -5.88
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 2 0.98 -0.03 -5.77
+flex-B+mDNAJB6-
3_(n=9)
1 1-3 3 0.83 -0.28 -6.01
+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 1 0.68 -0.55 -6.29
+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 2 0.67 -0.59 -6.33
+flex-B+mDNAJB6-
3_(n=9)
3 2-2/3-1 3 0.65 -0.62 -6.37
Anti-aggregation
+mDNAJB6-3_(n=15) 1 1-1 1 10.97 3.46 -1.53
+mDNAJB6-3_(n=15) 1 1-1 2 11.59 3.53 -1.45
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+mDNAJB6-3_(n=15) 1 1-1 3 11.84 3.57 -1.42
+mDNAJB6-3_(n=15) 1 1-2 1 10.95 3.45 -2.26
+mDNAJB6-3_(n=15) 1 1-2 2 11.88 3.57 -2.14
+mDNAJB6-3_(n=15) 1 1-2 3 12.61 3.66 -2.05
+mDNAJB6-3_(n=15) 1 1-3 1 7.56 2.92 -2.82
+mDNAJB6-3_(n=15) 1 1-3 2 7.55 2.92 -2.82
+mDNAJB6-3_(n=15) 1 1-3 3 7.57 2.92 -2.81
+mDNAJB6-3_(n=15) 2 2-1 1 12.21 3.61 -2.89
+mDNAJB6-3_(n=15) 2 2-1 2 13.56 3.76 -2.73
+mDNAJB6-3_(n=15) 2 2-1 3 13.51 3.76 -2.74
+mDNAJB6-3_(n=15) 2 2-2/3-1 1 7.29 2.87 -2.88
+mDNAJB6-3_(n=15) 2 2-2/3-1 2 7.18 2.84 -2.90
+mDNAJB6-3_(n=15) 2 2-2/3-1 3 7.53 2.91 -2.83
+mDNAJB6-2_(n=6) 2 2-1 1 149.65 7.23 0.73
+mDNAJB6-2_(n=6) 2 2-1 2 157.61 7.30 0.81
+mDNAJB6-2_(n=6) 2 2-1 3 164.98 7.37 0.87
+mDNAJB6-2_(n=6) 2 2-2/3-1 1 73.89 6.21 0.46
+mDNAJB6-2_(n=6) 2 2-2/3-1 2 77.95 6.28 0.54
+mDNAJB6-2_(n=6) 2 2-2/3-1 3 80.84 6.34 0.59
+mDNAJB6-1_(n=21) 1 1-1 1 0.97 -0.04 -5.02
+mDNAJB6-1_(n=21) 1 1-1 2 0.98 -0.03 -5.01
+mDNAJB6-1_(n=21) 1 1-1 3 1.04 0.05 -4.93
+mDNAJB6-1_(n=21) 1 1-2 1 1.05 0.08 -5.63
+mDNAJB6-1_(n=21) 1 1-2 2 1.00 0.00 -5.71
+mDNAJB6-1_(n=21) 1 1-2 3 1.14 0.19 -5.52
+mDNAJB6-1_(n=21) 1 1-3 1 2.82 1.50 -4.24
+mDNAJB6-1_(n=21) 1 1-3 2 2.41 1.27 -4.46
+mDNAJB6-1_(n=21) 1 1-3 3 2.46 1.30 -4.44
+mDNAJB6-1_(n=21) 2 2-1 1 3.31 1.73 -4.77
+mDNAJB6-1_(n=21) 2 2-1 2 3.36 1.75 -4.74
+mDNAJB6-1_(n=21) 2 2-1 3 3.46 1.79 -4.70
+mDNAJB6-1_(n=21) 2 2-2/3-1 1 2.56 1.35 -4.39
+mDNAJB6-1_(n=21) 2 2-2/3-1 2 2.46 1.30 -4.44
+mDNAJB6-1_(n=21) 2 2-2/3-1 3 2.36 1.24 -4.50
+mDNAJB6-1_(n=21) 3 2-2/3-1 1 2.62 1.39 -4.36
+mDNAJB6-1_(n=21) 3 2-2/3-1 2 2.59 1.37 -4.37
+mDNAJB6-1_(n=21) 3 2-2/3-1 3 2.59 1.37 -4.37
+mDNAJB6-1_(n=21) 3 3-2 1 7.56 2.92 -3.84
+mDNAJB6-1_(n=21) 3 3-2 2 6.75 2.75 -4.01
+mDNAJB6-1_(n=21) 3 3-2 3 6.55 2.71 -4.05
+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 1 2.02 1.02 -4.73
+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 2 1.88 0.91 -4.84
+mDNAJB6-1-
extended_(n=6)
3 2-2/3-1 3 1.73 0.79 -4.95
+mDNAJB6-1-
extended_(n=6)
3 3-2 1 4.98 2.31 -4.45
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+mDNAJB6-1-
extended_(n=6)
3 3-2 2 5.13 2.36 -4.40
+mDNAJB6-1-
extended_(n=6)
3 3-2 3 4.66 2.22 -4.54
+mDNAJC6_(n=9) 1 1-1 1 82.22 6.36 1.38
+mDNAJC6_(n=9) 1 1-1 2 80.44 6.33 1.35
+mDNAJC6_(n=9) 1 1-1 3 75.85 6.24 1.26
+mDNAJC6_(n=9) 1 1-2 1 83.06 6.38 0.67
+mDNAJC6_(n=9) 1 1-2 2 94.42 6.56 0.85
+mDNAJC6_(n=9) 1 1-2 3 63.22 5.98 0.27
+mDNAJC6_(n=9) 1 1-3 1 93.33 6.54 0.81
+mDNAJC6_(n=9) 1 1-3 2 65.23 6.03 0.29
+mDNAJC6_(n=9) 1 1-3 3 86.62 6.44 0.70
+mHSPA1A_(n=12) 1 1-0 1 10.61 3.41 -1.66
+mHSPA1A_(n=12) 1 1-0 2 11.65 3.54 -1.53
+mHSPA1A_(n=12) 1 1-0 3 11.52 3.53 -1.54
+mHSPA1A_(n=12) 1 1-1 1 16.02 4.00 -0.98
+mHSPA1A_(n=12) 1 1-1 2 18.68 4.22 -0.76
+mHSPA1A_(n=12) 1 1-1 3 20.19 4.34 -0.65
+mHSPA1A_(n=12) 1 1-2 1 27.56 4.78 -0.92
+mHSPA1A_(n=12) 1 1-2 2 28.41 4.83 -0.88
+mHSPA1A_(n=12) 1 1-2 3 27.75 4.79 -0.91
+mHSPA1A_(n=12) 1 1-3 1 28.34 4.82 -0.91
+mHSPA1A_(n=12) 1 1-3 2 25.14 4.65 -1.08
+mHSPA1A_(n=12) 1 1-3 3 27.66 4.79 -0.95
+mMITF_(n=6) 2 2-1 1 33.87 5.08 -1.41
+mMITF_(n=6) 2 2-1 2 39.72 5.31 -1.18
+mMITF_(n=6) 2 2-1 3 41.72 5.38 -1.11
+mMITF_(n=6) 2 2-2/3-1 1 30.66 4.94 -0.81
+mMITF_(n=6) 2 2-2/3-1 2 32.34 5.02 -0.73
+mMITF_(n=6) 2 2-2/3-1 3 31.50 4.98 -0.77
+mMME_(n=9) 1 1-1 1 4.22 2.08 -2.91
+mMME_(n=9) 1 1-1 2 4.65 2.22 -2.77
+mMME_(n=9) 1 1-1 3 4.28 2.10 -2.88
+mMME_(n=9) 1 1-2 1 6.25 2.64 -3.06
+mMME_(n=9) 1 1-2 2 5.06 2.34 -3.37
+mMME_(n=9) 1 1-2 3 5.98 2.58 -3.13
+mMME_(n=9) 1 1-3 1 4.35 2.12 -3.61
+mMME_(n=9) 1 1-3 2 4.46 2.16 -3.58
+mMME_(n=9) 1 1-3 3 4.41 2.14 -3.60
+mPCSK1N_(n=9) 1 1-1 1 18.04 4.17 -0.81
+mPCSK1N_(n=9) 1 1-1 2 20.79 4.38 -0.61
+mPCSK1N_(n=9) 1 1-2 1 31.39 4.97 -0.74
+mPCSK1N_(n=9) 1 1-2 2 31.23 4.96 -0.74
+mPCSK1N_(n=9) 1 1-2 3 31.61 4.98 -0.73
+mPCSK1N_(n=9) 1 1-3 1 25.63 4.68 -1.06
+mPCSK1N_(n=9) 1 1-3 2 26.52 4.73 -1.01
+mPCSK1N_(n=9) 1 1-3 3 24.81 4.63 -1.10
+mSCG5_(n=9) 1 1-1 1 10.24 3.36 -1.63
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+mSCG5_(n=9) 1 1-1 2 11.14 3.48 -1.51
+mSCG5_(n=9) 1 1-1 3 10.32 3.37 -1.62
+mSCG5_(n=9) 1 1-2 1 21.97 4.46 -1.25
+mSCG5_(n=9) 1 1-2 2 19.43 4.28 -1.43
+mSCG5_(n=9) 1 1-2 3 20.19 4.34 -1.37
+mSCG5_(n=9) 1 1-3 1 27.77 4.80 -0.94
+mSCG5_(n=9) 1 1-3 2 28.60 4.84 -0.90
+mSCG5_(n=9) 1 1-3 3 28.93 4.85 -0.88
Aggregation proteins
+mAPP_(n=18) 1 1-0 1 51.42 5.68 0.61
+mAPP_(n=18) 1 1-0 2 54.68 5.77 0.70
+mAPP_(n=18) 1 1-0 3 50.80 5.67 0.60
+mAPP_(n=18) 1 1-1 1 62.46 5.96 0.98
+mAPP_(n=18) 1 1-1 2 69.75 6.12 1.14
+mAPP_(n=18) 1 1-1 3 65.41 6.03 1.05
+mAPP_(n=18) 1 1-2 1 107.39 6.75 1.04
+mAPP_(n=18) 1 1-2 2 115.85 6.86 1.15
+mAPP_(n=18) 1 1-2 3 120.02 6.91 1.20
+mAPP_(n=18) 1 1-3 1 88.47 6.47 0.73
+mAPP_(n=18) 1 1-3 2 90.57 6.50 0.76
+mAPP_(n=18) 1 1-3 3 87.31 6.45 0.71
+mAPP_(n=18) 3 2-2/3-1 1 80.89 6.34 0.59
+mAPP_(n=18) 3 2-2/3-1 2 80.99 6.34 0.60
+mAPP_(n=18) 3 3-2 1 166.94 7.38 0.62
+mAPP_(n=18) 3 3-2 2 193.87 7.60 0.84
+mAPP_(n=18) 3 3-2 3 154.93 7.28 0.52
+mAPP-extended_(n=6) 3 2-2/3-1 1 78.47 6.29 0.55
+mAPP-extended_(n=6) 3 2-2/3-1 2 78.40 6.29 0.55
+mAPP-extended_(n=6) 3 2-2/3-1 3 83.35 6.38 0.64
+mAPP-extended_(n=6) 3 3-2 1 170.85 7.42 0.66
+mAPP-extended_(n=6) 3 3-2 2 153.17 7.26 0.50
+mAPP-extended_(n=6) 3 3-2 3 155.34 7.28 0.52
+mITM2B_(n=12) 1 1-0 1 11.24 3.49 -1.58
+mITM2B_(n=12) 1 1-0 2 10.82 3.44 -1.63
+mITM2B_(n=12) 1 1-0 3 10.15 3.34 -1.73
+mITM2B_(n=12) 1 1-1 1 13.79 3.79 -1.20
+mITM2B_(n=12) 1 1-1 2 16.46 4.04 -0.94
+mITM2B_(n=12) 1 1-1 3 19.29 4.27 -0.71
+mITM2B_(n=12) 1 1-2 1 16.61 4.05 -1.65
+mITM2B_(n=12) 1 1-2 2 15.14 3.92 -1.79
+mITM2B_(n=12) 1 1-2 3 16.53 4.05 -1.66
+mITM2B_(n=12) 1 1-3 1 21.56 4.43 -1.31
+mITM2B_(n=12) 1 1-3 2 25.02 4.64 -1.09
+mITM2B_(n=12) 1 1-3 3 22.55 4.50 -1.24
+mSNCA_(n=15) 1 1-1 1 31.63 4.98 0.00
+mSNCA_(n=15) 1 1-1 2 41.20 5.36 0.38
+mSNCA_(n=15) 1 1-1 3 42.17 5.40 0.41
+mSNCA_(n=15) 1 1-2 1 55.45 5.79 0.09
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+mSNCA_(n=15) 1 1-2 2 54.95 5.78 0.07
+mSNCA_(n=15) 1 1-2 3 54.48 5.77 0.06
+mSNCA_(n=15) 1 1-3 1 50.51 5.66 -0.08
+mSNCA_(n=15) 1 1-3 2 52.03 5.70 -0.03
+mSNCA_(n=15) 1 1-3 3 66.55 6.06 0.32
+mSNCA_(n=15) 3 2-2/3-1 1 52.61 5.72 -0.03
+mSNCA_(n=15) 3 2-2/3-1 2 54.15 5.76 0.02
+mSNCA_(n=15) 3 2-2/3-1 3 52.93 5.73 -0.02
+mSNCA_(n=15) 3 3-2 1 71.38 6.16 -0.60
+mSNCA_(n=15) 3 3-2 2 83.45 6.38 -0.38
+mSNCA_(n=15) 3 3-2 3 76.04 6.25 -0.51
+mSNCA-
extended_(n=6)
3 2-2/3-1 1 36.93 5.21 -0.54
+mSNCA-
extended_(n=6)
3 2-2/3-1 2 36.90 5.21 -0.54
+mSNCA-
extended_(n=6)
3 2-2/3-1 3 36.75 5.20 -0.54
+mSNCA-
extended_(n=6)
3 3-2 1 64.69 6.02 -0.74
+mSNCA-
extended_(n=6)
3 3-2 2 71.72 6.16 -0.60
+mSNCA-
extended_(n=6)
3 3-2 3 64.85 6.02 -0.74
+mIAPP-
extended_(n=6)
3 2-2/3-1 1 28.40 4.83 -0.92
+mIAPP-
extended_(n=6)
3 2-2/3-1 2 27.50 4.78 -0.96
+mIAPP-
extended_(n=6)
3 2-2/3-1 3 29.64 4.89 -0.85
+mIAPP-
extended_(n=6)
3 3-2 2 59.19 5.89 -0.87
+mIAPP-
extended_(n=6)
3 3-2 3 54.45 5.77 -0.99
+mPRNP-
extended_(n=6)
3 2-2/3-1 2 6.56 2.71 -3.03
+mPRNP-
extended_(n=6)
3 2-2/3-1 3 6.63 2.73 -3.01
+mPRNP-
extended_(n=6)
3 3-2 1 13.03 3.70 -3.06
+mPRNP-
extended_(n=6)
3 3-2 2 12.83 3.68 -3.08
+mPRNP-
extended_(n=6)
3 3-2 3 14.17 3.82 -2.94
+mACTB-
extended_(n=6)
3 2-2/3-1 2 89.57 6.48 0.74
+mACTB-
extended_(n=6)
3 2-2/3-1 3 95.35 6.58 0.83
+mACTB-
extended_(n=6)
3 3-2 1 172.96 7.43 0.67
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+mACTB-
extended_(n=6)
3 3-2 2 169.62 7.41 0.65
+mACTB-
extended_(n=6)
3 3-2 3 174.97 7.45 0.69
+mSOD1-
extended_(n=6)
3 2-2/3-1 1 13.01 3.70 -2.04
+mSOD1-
extended_(n=6)
3 2-2/3-1 2 13.62 3.77 -1.98
+mSOD1-
extended_(n=6)
3 2-2/3-1 3 13.00 3.70 -2.04
+mSOD1-
extended_(n=6)
3 3-2 1 29.97 4.91 -1.85
+mSOD1-
extended_(n=6)
3 3-2 2 28.43 4.83 -1.93
+mSOD1-
extended_(n=6)
3 3-2 3 29.12 4.86 -1.90
+mTRP53-
extended_(n=6)
3 2-2/3-1 1 9.85 3.30 -2.44
+mTRP53-
extended_(n=6)
3 2-2/3-1 2 9.48 3.25 -2.50
+mTRP53-
extended_(n=6)
3 2-2/3-1 3 9.88 3.30 -2.44
+mTRP53-
extended_(n=6)
3 3-2 1 17.87 4.16 -2.60
+mTRP53-
extended_(n=6)
3 3-2 2 19.43 4.28 -2.48
+mTRP53-
extended_(n=6)
3 3-2 3 16.04 4.00 -2.76
Neuron survival
+mGDF11_(n=6) 2 2-1 1 0.17 -2.58 -9.07
+mGDF11_(n=6) 2 2-1 2 0.16 -2.67 -9.16
+mGDF11_(n=6) 2 2-1 3 0.14 -2.87 -9.36
+mGDF11_(n=6) 2 2-2/3-1 1 0.09 -3.49 -9.23
+mGDF11_(n=6) 2 2-2/3-1 2 0.08 -3.69 -9.43
+mGDF11_(n=6) 2 2-2/3-1 3 0.08 -3.70 -9.44
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 1 4.16 2.06 -3.02
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 2 4.28 2.10 -2.97
+mGDNF+60bp
(+SV40)_(n=18)
1 1-0 3 4.48 2.16 -2.91
+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 1 3.50 1.81 -3.17
+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 2 3.84 1.94 -3.04
+mGDNF+60bp
(+SV40)_(n=18)
1 1-1 3 4.05 2.02 -2.96
+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 1 5.22 2.38 -3.32
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+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 2 3.81 1.93 -3.78
+mGDNF+60bp
(+SV40)_(n=18)
1 1-2 3 4.60 2.20 -3.51
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 1 8.37 3.07 -2.67
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 2 5.92 2.57 -3.17
+mGDNF+60bp
(+SV40)_(n=18)
1 1-3 3 7.86 2.97 -2.76
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 1 8.91 3.15 -3.34
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 2 7.63 2.93 -3.56
+mGDNF+60bp
(+SV40)_(n=18)
2 2-1 3 9.02 3.17 -3.32
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 1 6.22 2.64 -3.11
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 2 6.00 2.59 -3.16
+mGDNF+60bp
(+SV40)_(n=18)
2 2-2/3-1 3 5.87 2.55 -3.19
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 1 6.97 2.80 -3.69
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 2 5.33 2.41 -4.08
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-1 3 5.20 2.38 -4.12
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 1 4.15 2.05 -3.69
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 2 4.00 2.00 -3.74
+mGDNF+60bp
(no_SV40)_(n=6)
2 2-2/3-1 3 4.23 2.08 -3.66
+mPARK2-1_(n=9) 1 1-1 1 4.78 2.26 -2.73
+mPARK2-1_(n=9) 1 1-1 2 5.39 2.43 -2.55
+mPARK2-1_(n=9) 1 1-1 3 5.26 2.39 -2.59
+mPARK2-1_(n=9) 1 1-2 1 6.04 2.59 -3.11
+mPARK2-1_(n=9) 1 1-2 2 6.09 2.61 -3.10
+mPARK2-1_(n=9) 1 1-2 3 6.76 2.76 -2.95
+mPARK2-1_(n=9) 1 1-3 1 5.53 2.47 -3.27
+mPARK2-1_(n=9) 1 1-3 2 5.32 2.41 -3.32
+mPARK2-1_(n=9) 1 1-3 3 5.33 2.41 -3.32
Co-transfection ratio testing
(+SV40)-1:10_(n=3) 3 3-2 1 174.77 7.45 0.69
(+SV40)-1:10_(n=3) 3 3-2 2 192.46 7.59 0.83
(+SV40)-1:10_(n=3) 3 3-2 3 182.85 7.51 0.75
(+SV40)-1:25_(n=3) 3 3-2 1 391.61 8.61 1.85
(+SV40)-1:25_(n=3) 3 3-2 2 385.02 8.59 1.83
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(+SV40)-1:25_(n=3) 3 3-2 3 398.29 8.64 1.88
+mAPP-1:10_(n=3) 3 3-2 1 179.11 7.48 0.72
+mAPP-1:10_(n=3) 3 3-2 2 182.05 7.51 0.75
+mAPP-1:10_(n=3) 3 3-2 3 183.51 7.52 0.76
+mAPP-1:25_(n=3) 3 3-2 1 501.47 8.97 2.21
+mAPP-1:25_(n=3) 3 3-2 2 600.76 9.23 2.47
+mAPP-1:25_(n=3) 3 3-2 3 512.31 9.00 2.24
(+SV40)-1:10_(n=3) 4 4-0 1 207.87 7.70 N/A
(+SV40)-1:10_(n=3) 4 4-0 2 200.95 7.65 N/A
(+SV40)-1:10_(n=3) 4 4-0 3 199.05 7.64 N/A
+mAPP-1:10_(n=3) 4 4-0 1 205.57 7.68 N/A
+mAPP-1:10_(n=3) 4 4-0 2 191.60 7.58 N/A
+mAPP-1:10_(n=3) 4 4-0 3 190.25 7.57 N/A
(+SV40)-1:20_(n=3) 4 4-0 1 387.94 8.60 N/A
(+SV40)-1:20_(n=3) 4 4-0 2 430.05 8.75 N/A
(+SV40)-1:20_(n=3) 4 4-0 3 406.74 8.67 N/A
+mAPP-1:20_(n=3) 4 4-0 1 398.86 8.64 N/A
+mAPP-1:20_(n=3) 4 4-0 2 447.65 8.81 N/A
+mAPP-1:20_(n=3) 4 4-0 3 388.16 8.60 N/A
(+SV40)-1:40_(n=3) 4 4-0 1 819.04 9.68 N/A
(+SV40)-1:40_(n=3) 4 4-0 2 775.96 9.60 N/A
(+SV40)-1:40_(n=3) 4 4-0 3 741.35 9.53 N/A
+mAPP-1:40_(n=3) 4 4-0 1 813.43 9.67 N/A
+mAPP-1:40_(n=3) 4 4-0 2 815.26 9.67 N/A
+mAPP-1:40_(n=3) 4 4-0 3 756.38 9.56 N/A
(+SV40)-1:80_(n=3) 4 4-0 1 1,673.97 10.71 N/A
(+SV40)-1:80_(n=3) 4 4-0 2 1,662.37 10.70 N/A
(+SV40)-1:80_(n=3) 4 4-0 3 1,568.60 10.62 N/A
+mAPP-1:80_(n=3) 4 4-0 1 1,622.58 10.66 N/A
+mAPP-1:80_(n=3) 4 4-0 2 1,820.20 10.83 N/A
+mAPP-1:80_(n=3) 4 4-0 3 1,722.24 10.75 N/A
(+SV40)-1:160_(n=3) 4 4-0 1 3,526.74 11.78 N/A
(+SV40)-1:160_(n=3) 4 4-0 2 3,518.28 11.78 N/A
(+SV40)-1:160_(n=3) 4 4-0 3 3,381.68 11.72 N/A
+mAPP-1:160_(n=3) 4 4-0 1 3,448.59 11.75 N/A
+mAPP-1:160_(n=3) 4 4-0 2 3,111.83 11.60 N/A
+mAPP-1:160_(n=3) 4 4-0 3 3,270.53 11.68 N/A
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